Questions

1. Phenotypic Matching:
   • Chorea: Rapid, involuntary, non-rhythmic, unsustained, unpredictable, purposeless, jerky movements flowing randomly from one body region to another.
   • Athetosis: Slow, continuous, smooth, sinuous, writhing movements predominantly affecting the distal extremities.
   • Dystonia: Involuntary, sustained or intermittent muscle contractions causing abnormal, often repetitive, twisting movements and patterned postures.
   • Ballismus: Large-amplitude, violent, flinging, proximal limb movements, usually unilateral (hemiballismus).
   • Myoclonus: Sudden, brief, shock-like involuntary single or multiple muscle contractions (positive) or lapses of contraction (negative myoclonus/asterixis).
   • Tics: Stereotyped, repetitive, non-rhythmic, patterned movements or vocalizations preceded by an internal premonitory urge.
2. Clinical Maneuvers to Accentuate Chorea:
   • Milkmaid’s grip: Inability to maintain sustained squeeze of the examiner's fingers due to intermittent tonic relaxations.
   • Jack-in-the-box tongue (Chameleon tongue): Inability to keep the tongue continuously protruded beyond the lips for >10–20 seconds.
   • Pronator sign / Spooning: Hyperpronation of forearms with hyperextension of metacarpophalangeal joints and flexion of wrists when arms are raised overhead.
   • Piano-playing sign: Involuntary pseudo-pianistic fingering movements elicited when arms are extended horizontally with eyes closed.
3. Distinction Between Tics and Chorea:
   • Premonitory urge: Present in tics (internal sensory premonition relieved by the movement); absent in chorea.
   • Suppressibility: Tics can be voluntarily suppressed temporarily at the expense of mounting inner tension; chorea cannot be voluntarily suppressed.
   • Stereotypy: Tics are repetitive and stereotyped (same muscle groups recruited identically); chorea is continuously changing, random, and non-stereotyped.
   • Sleep effect: Simple tics may rarely persist into non-REM sleep; choreic movements universally cease completely during sleep.
4. Pharmacotherapy and Dosing:
   • Severe Sydenham Chorea:
     • Sodium Valproate: 15–20 mg/kg/day orally divided q8h or q12h, titrating up to 30–40 mg/kg/day (or Haloperidol 0.025–0.05 mg/kg/day divided q8h).
   • Acute Drug-Induced Dystonia:
     • Promethazine: 0.5–1 mg/kg/dose IV/IM (maximum 25 mg) OR Diphenhydramine: 1–1.25 mg/kg/dose IV/IM over 3–5 minutes (maximum 50 mg/dose).

1. Primary Diagnosis:
   • Acute post-infectious cerebellar ataxia (Acute cerebellitis), secondary to Varicella-Zoster virus infection.
2. Differential Diagnoses:
   • Posterior fossa mass lesion: Medulloblastoma, juvenile pilocytic astrocytoma, or ependymoma with acute intratumoral hemorrhage.
   • Toxic ingestion / Involuntary intoxication: Anticonvulsants (phenytoin, carbamazepine), antihistamines, alcohol, benzodiazepines.
   • Acute peripheral neuropathy variant: Miller Fisher syndrome (triad of ataxia, ophthalmoplegia, and areflexia).
   • Acute demyelination: Acute Disseminated Encephalomyelitis (ADEM).
   • Neuroblastoma-associated paraneoplastic syndrome: Opsoclonus-myoclonus-ataxia syndrome (OMAS).
3. CSF Findings and Neuroimaging Indications:
   • CSF Profile: Normal opening pressure; mild lymphocytic pleocytosis (<30–50 cells/mm³); normal or mildly elevated protein (50–80 mg/dL); normal glucose; negative Gram stain, bacterial culture, and viral PCRs.
   • Indications for Urgent MRI:
     • Asymmetric, strictly unilateral cerebellar signs.
     • Depressed sensorium, persistent encephalopathy, or focal cranial nerve palsies.
     • Signs of raised intracranial pressure (papilledema, Cushing triad).
     • Progression of ataxia beyond 7 days or failure of spontaneous recovery after 3–4 weeks.
4. Management and Prognosis:
   • Supportive care: Fall precautions, supervision of ambulation, physical therapy, and reassurance.
   • Natural course: Benign and self-limiting; gradual spontaneous recovery typically commences within 2 to 4 weeks, with complete resolution within 2 to 3 months in >80–90% of children.
   • Immunomodulation: Reserved for severe, fulminant acute cerebellitis with life-threatening cerebellar swelling, brainstem compression, or tonsillar herniation: IV Methylprednisolone 30 mg/kg/day (maximum 1000 mg/day) for 3 to 5 days.

1. Diagnosis:
   • Acute Disseminated Encephalomyelitis (ADEM).
2. Associated Autoantibody:
   • Anti-Myelin Oligodendrocyte Glycoprotein antibody (MOG-IgG).
3. Co-involved Extracerebral CNS Regions:
   • Spinal cord: Acute transverse myelitis (often longitudinally extensive).
   • Optic nerves: Bilateral or unilateral acute optic neuritis.
4. First-Line Treatment Protocol:
   • Induction: IV Methylprednisolone at 30 mg/kg/day (maximum 1000 mg/day) diluted in normal saline, infused over 1 hour once daily for 3 to 5 consecutive days.
   • Oral Taper: Oral Prednisolone initiated at 1 to 2 mg/kg/day (single morning dose) starting on day 6, with a gradual taper over 4 to 6 weeks to prevent relapse.
   • Refractory / Steroid-unresponsive rescue: Intravenous Immunoglobulin (IVIG) at a total dose of 2 g/kg administered over 2 to 5 days (e.g., 1 g/kg/day for 2 days or 400 mg/kg/day for 5 days) OR Therapeutic Plasma Exchange (PLEX; 5–7 cycles on alternate days).

1. Diagnosis and Neuroimaging Pattern:
   • Diagnosis: Acute Necrotizing Encephalopathy of Childhood (ANEC).
   • MRI Pattern: Symmetric, multifocal "tricolor" concentric laminar lesions characteristically involving bilateral thalami:
     • Center: Hemorrhage/cavitation/necrosis (hypointense on T1, hyperintense/mixed on T2, blooming on SWI/GRE).
     • Intermediate ring: Cytotoxic edema (restricted diffusion on DWI/ADC).
     • Outer ring: Vasogenic edema (hyperintense on T2/FLAIR).
     • Additional involvement: Brainstem tegmentum, periventricular cerebral white matter, and cerebellar internal nuclei.
2. Viral Precipitants and Genetic Etiology:
   • Viral triggers: Influenza A (H1N1, H3N2), Influenza B, and Human Herpesvirus 6 (HHV-6).
   • Genetic mutation: Heterozygous missense mutation in the RANBP2 (Ran-Binding Protein 2) gene on chromosome 2q12.1–q13 (causes autosomal dominant ANE1 with incomplete penetrance).
3. Laboratory Profile:
   • Serum Transaminases: Markedly elevated (AST and ALT > 3 to 10 times upper limit of normal).
   • Serum Ammonia: Normal or only mildly elevated (differentiating ANEC from Reye syndrome).
   • CSF Biochemistry: Marked albuminocytological dissociation—significantly elevated CSF protein without pleocytosis (normal cell count), sterile cultures, and negative viral PCRs.
4. Emergency Hyperinflammation Protocol:
   • Pulse Corticosteroid Therapy: IV Methylprednisolone 30 mg/kg/day (maximum 1000 mg/day) once daily for 3 to 5 days, initiated within 24 hours of onset.
   • Intravenous Immunoglobulin (IVIG): Total dose 2 g/kg IV administered as 1 g/kg/day over 2 consecutive days.
   • IL-6 Receptor Antagonist (in severe cytokine storm): Tocilizumab: 12 mg/kg IV single dose (if body weight < 30 kg) or 8 mg/kg IV (if body weight ≥ 30 kg).

1. Contraindications to Immediate Lumbar Puncture:
   • Signs of impending transtentorial or cerebellar herniation / severely raised ICP: Asymmetric pupillary reactivity, focal motor deficits, decerebrate/decorticate posturing, abnormal breathing patterns, or Cushing triad (bradycardia, hypertension, irregular respirations).
   • Severe cardiovascular or respiratory instability (shock, respiratory failure requiring urgent intubation).
   • Infection of the skin and subcutaneous soft tissues over the planned needle puncture site (lumbar area).
   • Severe bleeding diathesis, active coagulopathy, or severe thrombocytopenia (platelet count < 50,000/mm³).
2. Indications for Cranial CT Prior to Lumbar Puncture:
   • New focal neurological deficits (e.g., focal seizures, hemiparesis, cranial nerve palsies, unequal pupils).
   • Deeply depressed sensorium or coma (GCS < 10–12).
   • Presence of papilledema on fundoscopic examination.
   • Severe immunocompromised state (e.g., advanced HIV, post-transplant, chemotherapy).
3. Bacterial Etiologies:
   • Streptococcus pneumoniae (Pneumococcus).
   • Neisseria meningitidis (Meningococcus).
   • Haemophilus influenzae type b (Hib) (particularly in unimmunized or under-immunized children).
4. Empirical Antimicrobial and Adjunctive Protocol:
   • Third-Generation Cephalosporin:
     • Ceftriaxone: 100 mg/kg/day IV once daily or divided q12h (maximum 4 g/day) OR Cefotaxime: 200–300 mg/kg/day IV divided q6h (maximum 12 g/day).
   • Glycopeptide (for Cephalosporin-resistant S. pneumoniae):
     • Vancomycin: 60 mg/kg/day IV divided q6h (infused over 60 minutes; maximum 2 g/day).
   • Adjunctive Corticosteroid:
     • Dexamethasone: 0.15 mg/kg/dose IV q6h for 2 to 4 days (or 0.4 mg/kg/dose q12h for 2 days).
     • Timing: Administer 10 to 20 minutes prior to, or at least concurrently with, the first dose of parenteral antibiotics (ineffective if administered > 1 hour after antibiotic initiation).

1. Differential Diagnoses:
   • Acute transverse myelitis (ATM)
   • Acute compressive spinal cord lesion (epidural abscess, tubercular Pott spine, or epidural hematoma)
   • Neuromyelitis optica spectrum disorder (NMOSD) / Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
   • Guillain-Barré syndrome (acute motor-sensory axonal neuropathy or acute inflammatory demyelinating polyradiculoneuropathy presenting during spinal shock)
2. Neuroimaging Modality and Findings:
   • Modality: Urgent magnetic resonance imaging (MRI) of the entire spine with and without intravenous gadolinium contrast (along with brain MRI to exclude demyelinating dissemination).
   • Characteristic findings:
     • Hyperintense signal on T2-weighted and STIR sequences extending longitudinally across $\ge 2$ vertebral segments, predominantly involving central cord gray matter (>50% of cross-sectional cord area).
     • Cord expansion with patchy, variable gadolinium enhancement on T1 post-contrast sequences.
3. TMCWG Diagnostic Criteria:
   • Sensory, motor, or autonomic dysfunction attributable to the spinal cord.
   • Bilateral signs and/or symptoms (not necessarily symmetric).
   • Clearly defined sensory level.
   • Demonstration of spinal cord inflammation: cerebrospinal fluid (CSF) pleocytosis (>5 WBCs/$\mu\text{L}$) or elevated IgG index, OR gadolinium enhancement on spinal MRI.
   • Exclusion of extra-axial compressive, post-radiation, neoplastic, or vascular etiologies.
   • Progression to nadir between 4 hours and 21 days from symptom onset.
4. Management Protocol:
   • First-line Therapy: Intravenous Methylprednisolone:
     $$ > \begin{aligned} > \text{Dose} &= 30\text{ mg/kg/day (maximum 1000 mg/day)} \\ > &= 24\text{ kg} \times 30\text{ mg/kg/day} = \mathbf{720\text{ mg/day}} \\ > \text{Administration} &= \text{Infused IV in 100--200 mL normal saline over 2 hours once daily for 3--5 days} > \end{aligned} > $$
     Followed by oral prednisolone taper ($1\text{ mg/kg/day}$) over 2 to 4 weeks.
   • Rescue Therapy: Therapeutic Plasma Exchange (PLEX) (5 to 7 cycles on alternate days over 10 to 14 days) or Intravenous Immunoglobulin (IVIG: $2\text{ g/kg}$ total dose administered as $1\text{ g/kg/day}$ over 2 consecutive days or $400\text{ mg/kg/day}$ for 5 days).

graph TD
    A[Acute Flaccid Paraparesis with Sensory Level] --> B[Urgent Whole-Spine MRI with Gadolinium]
    B --> C{Compressive Etiology?}
    C -- Yes --> D[Urgent Neurosurgical Decompression]
    C -- No --> E[Lumbar Puncture + Autoimmune Biomarkers]
    E --> F[Confirm ATM / TMCWG Criteria]
    F --> G[IV Methylprednisolone 30 mg/kg/d x 3-5 days]
    G --> H{Clinical Improvement at Day 5?}
    H -- Yes --> I[Oral Prednisolone Taper x 2-4 weeks]
    H -- No --> J[Rescue: Therapeutic Plasma Exchange 5-7 cycles OR IVIG 2 g/kg]

1. Neuroimaging Abnormalities:
   • Large, patchy, ill-defined, asymmetric hyperintensities on T2-weighted and FLAIR sequences.
   • Predominant involvement of bilateral subcortical and deep cerebral white matter (corona radiata, centrum semiovale) with concurrent involvement of deep gray matter nuclei (thalami and basal ganglia).
2. Diagnosis & Differential:
   • Primary Diagnosis: Acute Disseminated Encephalomyelitis (ADEM).
   • Principal Differential: Pediatric Multiple Sclerosis (MS).
3. Differentiating Features:

   Feature	Acute Disseminated Encephalomyelitis (ADEM)	Pediatric Multiple Sclerosis (MS)
   Encephalopathy	Mandatory diagnostic criterion (lethargy, irritability, behavioral change)	Absent or rare; alertness typically preserved
   Clinical Course	Typically monophasic (single clinical episode)	Relapsing-remitting (dissemination in time)
   Lesion Morphology on MRI	Large (>1--2 cm), fluffy, ill-defined, asymmetric; deep gray matter frequently involved	Small, well-demarcated, ovoid, periventricular ("Dawson fingers"), corpus callosum involvement
   CSF Oligoclonal Bands (OCBs)	Typically negative or transiently positive (<30%)	Persistently positive in >80--90% of cases

4. Pharmacotherapy:
   • Intravenous Pulse Methylprednisolone:
     • Dose: $30\text{ mg/kg/day}$ IV (maximum $1000\text{ mg/day}$) infused over 2 hours once daily for 3 to 5 consecutive days.
   • Oral Glucocorticoid Taper:
     • Follow IV pulses with oral prednisolone at $1\text{ to }2\text{ mg/kg/day}$ for 1 to 2 weeks, followed by a gradual tapering schedule over a total duration of 4 to 6 weeks to prevent rebound demyelination.

1. Culprit Antiseizure Medications:
   • Child A: Topiramate (causes carbonic anhydrase inhibition leading to renal tubular acidosis and ciliochoroidal effusion with anterior lens displacement causing angle-closure glaucoma; sweat gland carbonic anhydrase inhibition causes hypohidrosis).
   • Child B: Sodium Valproate (valproate-induced hyperammonemic encephalopathy).
   • Child C: Lamotrigine (highest risk of severe mucocutaneous reactions during initial rapid dose titration or when combined with valproate).
   • Child D: Vigabatrin (irreversible retinal toxicity targeting horizontal and amacrine cells causing peripheral visual field constriction).
2. Pathophysiology and Antidote for Child B:
   • Biochemical Mechanism: Valproate metabolites (valproyl-CoA and 4-pentenoic acid) deplete mitochondrial coenzyme A and carnitine. This inhibits carbamoyl phosphate synthetase I (CPS-I), the rate-limiting enzyme of the hepatic urea cycle, resulting in systemic ammonia accumulation without causing hepatocellular necrosis.
   • Specific Antidote: Intravenous or oral L-Carnitine ($100\text{ mg/kg}$ loading dose IV over 30 minutes [max $6\text{ g}$], followed by $50\text{ mg/kg/dose}$ IV every 8 hours until clinical resolution and ammonia normalizes).
3. Pharmacogenomic Marker:
   • HLA-B*1502 allele (screening is strongly recommended in patients of Southeast Asian and South Asian descent due to a high risk of Stevens-Johnson syndrome / Toxic Epidermal Necrolysis).
4. Levetiracetam Dosing Calculation:
   $$ > \begin{aligned} > \text{Loading Dose} &= 60\text{ mg/kg IV bolus (infused over 10--15 minutes)} \\ > &= 20\text{ kg} \times 60\text{ mg/kg} = \mathbf{1200\text{ mg}} \quad (\text{Maximum standard load: } 4500\text{ mg}) \\ > \text{Daily Maintenance Dose} &= 30\text{ mg/kg/day divided every 12 hours} \\ > &= 20\text{ kg} \times 30\text{ mg/kg/day} = \mathbf{600\text{ mg/day}} \\ > &= \mathbf{300\text{ mg IV/oral every 12 hours}} > \end{aligned} > $$

1. Diagnosis:
   • Ataxia-Telangiectasia (Louis-Bar syndrome).
2. Genetic Basis:
   • Gene: ATM (Ataxia-Telangiectasia Mutated) gene.
   • Chromosomal Locus: Chromosome 11q22.3.
   • Mode of Inheritance: Autosomal Recessive.
3. Serum Biochemical Marker:
   • Elevated Serum Alpha-Fetoprotein (AFP) (elevated in $>95\%$ of affected children after 1--2 years of age; typically $>10\text{--}20\text{ ng/mL}$).
4. Non-Neurological Complications for Surveillance:
   • Primary Immunodeficiency: Combined humoral and cellular immunodeficiency (selective IgA, IgG subclass deficiency, and lymphopenia) leading to recurrent sinopulmonary infections and bronchiectasis.
   • Malignancy: Significantly increased lifetime risk ($\approx 25\text{--}30\%$) of hematologic (acute lymphoblastic leukemia, T-cell prolymphocytic leukemia, non-Hodgkin lymphoma) and solid epithelial tumors.
   • Extreme Radiosensitivity: Hypersensitivity to ionizing radiation secondary to defective DNA double-strand break repair (diagnostic X-rays/CT scans and radiotherapy are contraindicated unless strictly essential).
   • Endocrinopathy: Severe insulin-resistant diabetes mellitus, growth retardation, and hypergonadotropic hypogonadism.

1. Most Probable Diagnosis:
   • Bell's Palsy (Acute idiopathic lower motor neuron facial [VIIth cranial] nerve paralysis).
2. Differentiating Features (UMN vs. LMN Facial Palsy):

   Diagnostic Feature	Upper Motor Neuron (UMN) Lesion	Lower Motor Neuron (LMN) Lesion
   Forehead Wrinkling	Preserved (frontalis muscle spared due to bilateral corticobulbar innervation)	Lost completely on ipsilateral side (frontalis paralyzed)
   Eye Closure	Preserved (orbicularis oculi spared)	Impaired/Incomplete (lagophthalmos on affected side)
   Associated Neurological Signs	Frequently associated with ipsilateral hemiparesis/spasticity (cortical/capsular lesion)	Isolated facial weakness; may have altered taste (anterior 2/3 tongue) or hyperacusis

3. Bell's Phenomenon:
   • Definition: A physiological reflexive upward and outward rotation of the eyeball upon attempting eyelid closure.
   • Pathophysiology: This is a normal protective ocular synkinesis between the facial and oculomotor motor nuclei. It is usually concealed by normal eyelid closure but becomes clearly visible in LMN facial palsy due to weakness of the orbicularis oculi (lagophthalmos).
4. Comprehensive Treatment Regimen:
   • Systemic Corticosteroid Therapy:
     • Oral Prednisolone: $1\text{ to }2\text{ mg/kg/day}$ (maximum $60\text{ mg/day}$) orally once daily for 7 to 10 days, initiated within 72 hours of onset. A short taper over 3 to 5 days may be utilized.
   • Eye Care and Corneal Protection (Critical to prevent exposure keratitis):
     • Instillation of lubricating artificial tear drops (e.g., carboxymethylcellulose $0.5\%$) every 1 to 2 hours while awake.
     • Application of ophthalmic lubricating ointment (polyethylene glycol or white petrolatum) inside the conjunctival sac at bedtime.
     • Taping the left eyelid shut or using an eye patch during sleep to ensure complete closure.

1. Primary Diagnosis:
   • Right-sided cerebral abscess (brain abscess) with elevated intracranial pressure and secondary left hemiparesis.
2. Pathophysiological Mechanisms:
   • Loss of Pulmonary Phagocytic Filter: Uncorrected right-to-left intracardiac shunting bypasses the pulmonary capillary network, which normally filters circulating bacteria, allowing transient bacteremia to seed the cerebral circulation directly.
   • Microvascular Thrombosis and Focal Ischemia: Secondary polycythemia (erythrocytosis) induced by chronic hypoxemia elevates blood viscosity, predisposing to microvascular sludging, microthrombosis, and focal cerebral infarction that provides a devitalized nidus for bacterial seeding and abscess formation.
3. Neuroimaging and Contraindication:
   • Imaging of Choice: Contrast-enhanced Magnetic Resonance Imaging (MRI) of the brain with Diffusion-Weighted Imaging (DWI) and Apparent Diffusion Coefficient (ADC) mapping.
   • Characteristic Findings: Smooth, well-defined thin ring-enhancing lesion surrounded by vasogenic edema on T1 post-contrast; hyperintense center with restricted diffusion on DWI (hypointense on ADC); hypointense rim on T2-weighted images.
   • Contraindication to Lumbar Puncture: Presence of a large intracranial space-occupying lesion with surrounding mass effect and papilledema poses an imminent risk of transtentorial (uncal) or tonsillar herniation; additionally, CSF yields poor diagnostic microbiological utility in non-ruptured brain abscesses.
4. Management Protocol:
   • Empirical Intravenous Antibiotic Regimen (minimum 6–8 weeks):
     • Ceftriaxone: $100\text{ mg/kg/day}$ IV divided q12h (or Cefotaxime $200\text{–}300\text{ mg/kg/day}$ IV divided q6h) to cover Streptococcus species (S. anginosus/viridans) and Enterobacteriaceae.
     • Metronidazole: $30\text{ mg/kg/day}$ IV divided q8h to cover anaerobic organisms (Bacteroides, Fusobacterium, Peptostreptococcus).
     • Vancomycin: $60\text{ mg/kg/day}$ IV divided q6h to cover methicillin-resistant Staphylococcus aureus (MRSA).
   • Indications for Neurosurgical Aspiration/Excision:
     • Abscess diameter $\ge 2.5\text{ cm}$.
     • Significant mass effect, midline shift $\ge 5\text{ mm}$, or imminent risk of intraventricular rupture.
     • Failure of abscess reduction or clinical neurological deterioration after 2 weeks of targeted medical therapy.

flowchart TD
    A[Cyanotic Congenital Heart Disease] --> B[Right-to-Left Shunt]
    A --> C[Chronic Hypoxemia]
    B --> D[Bypasses Pulmonary Capillary Filter]
    C --> E[Secondary Polycythemia & Hyperviscosity]
    E --> F[Microvascular Thrombosis & Focal Tissue Hypoxia]
    D & F --> G[Seeding of Ischemic Brain by Transient Bacteremia]
    G --> H[Cerebritis Phase 1 to 3 Days]
    H --> I[Early to Late Capsule Formation Brain Abscess]
    I --> J[Ring-Enhancing Mass Effect & Focal Deficit]

1. Diagnosis and Inheritance:
   • Diagnosis: Canavan disease (Spongy degeneration of the central nervous system / aspartoacylase deficiency).
   • Inheritance Pattern: Autosomal recessive.
2. Enzyme Defect and Gene:
   • Deficient Enzyme: Aspartoacylase (aminoacylase 2).
   • Mutated Gene: ASPA gene located on chromosome 17p13.2.
3. Neuroimaging and MRS Features:
   • MRI Brain Findings:
     • Diffuse, symmetric, confluent cerebral white matter T2/FLAIR hyperintensity and T1 hypointensity with prominent, early involvement of subcortical U-fibers (sparing internal capsule and corpus callosum initially).
     • Bilateral involvement of globus pallidus and thalamus with characteristic sparing of the putamen and caudate nucleus.
   • MRS Pathognomonic Peak: Markedly elevated N-acetylaspartate (NAA) peak (at 2.02 ppm) relative to creatine and choline.
4. Biomarker and Supportive Management:
   • Urinary Biomarker: Massively elevated free N-acetylaspartic acid (NAA) on urine organic acid analysis by gas chromatography-mass spectrometry (GC-MS).
   • Supportive Management:
     • Seizure management with antiseizure medications (e.g., Levetiracetam, Valproate).
     • Nutritional and bulbar support including gastrostomy feeding for dysphagia to prevent aspiration pneumonia.
     • Physical and occupational therapy with specialized seating and orthotics to manage spasticity and joint contractures; genetic counseling for parents with prenatal testing in subsequent pregnancies.

1. Causes of Xanthochromia:
   • Subarachnoid hemorrhage (hemoglobin breakdown into oxyhemoglobin and bilirubin $\ge 2\text{–}4\text{ hours}$ post-bleed).
   • Severe hyperbilirubinemia / systemic jaundice (serum total bilirubin $> 10\text{–}15\text{ mg/dL}$).
   • Markedly elevated CSF protein content ($> 150\text{–}400\text{ mg/dL}$).
   • Traumatic tap with delayed centrifugation ($> 1\text{ hour}$), resulting in in vitro red cell lysis.
2. Marked CSF Protein Elevation and Eponym:
   • Causes of Protein $> 400\text{ mg/dL}$:
     • Complete spinal block due to compressive spinal cord mass, tumor, or arachnoiditis (spinal obstruction).
     • Severe tuberculous meningitis with arachnoiditis/thick basal exudates.
     • Severe Guillain-Barré syndrome (late stage with prominent albuminocytologic dissociation).
   • Eponym: Froin's syndrome (characterized by marked xanthochromia, hyperproteinosis, and rapid spontaneous coagulation/clot formation of CSF).
3. Calculation and Interpretation:
   $$ > \begin{aligned} > \text{CSF-to-Serum Glucose Ratio} &= \frac{\text{CSF Glucose}}{\text{Simultaneous Serum Glucose}} \\ > &= \frac{24\text{ mg/dL}}{120\text{ mg/dL}} \\ > &= \mathbf{0.20} \quad (\text{Normal Reference Range: } 0.60\text{–}0.66 \text{ or } \ge 60\%) > \end{aligned} > $$
   • Interpretation: Marked hypoglycorrhachia (ratio $< 0.40$), indicating impaired blood-brain barrier glucose transport or elevated glycolytic consumption.
   • Non-infectious Causes of Hypoglycorrhachia:
     • Meningeal carcinomatosis or leukemic/lymphomatous infiltration.
     • Subarachnoid hemorrhage (delayed glycolytic consumption by erythrocytes).
     • GLUT1 (glucose transporter 1) deficiency syndrome.
4. Traumatic Tap vs. Subarachnoid Hemorrhage Differentiation:
   • Three-Tube Test: Clearing of erythrocyte count from tube 1 to tube 3 indicates traumatic tap; uniform erythrocyte counts across all tubes indicate subarachnoid hemorrhage.
   • Supernatant Xanthochromia: Clear, colorless supernatant after immediate centrifugation within 15 minutes indicates traumatic tap; pink/yellow xanthochromic supernatant confirms subarachnoid hemorrhage.
   • Presence of Erythrophages / Hemosiderin: Microscopic detection of erythrophages or hemosiderin-laden macrophages in CSF cytology indicates true in vivo bleeding ($\ge 12\text{–}18\text{ hours}$ old), absent in acute traumatic tap.

1. EEG Findings and Diagnosis:
   • Electrographic Abnormality: Generalized, bilateral, synchronous, symmetrical $3\text{ Hz}$ ($2.5\text{–}3.5\text{ Hz}$) spike-and-slow-wave complexes with sudden onset and abrupt termination against a normal background.
   • Diagnosis: Childhood Absence Epilepsy (CAE / Pyknolepsy).
2. Bedside Provocation Technique:
   • Maneuver: Voluntary hyperventilation.
   • Execution Protocol: The child is asked to blow forcefully and continuously on a pinwheel, tissue paper, or imaginary candle for 3 to 4 minutes at a rate of 25 to 30 breaths per minute while breathing deeply. This induces respiratory alkalosis and cerebral vasoconstriction, reliably triggering the typical absence seizure in $> 90\%$ of untreated patients.
3. Subtypes and Genetic Metabolic Defect:
   • Subtypes/Variants of Absence Seizures: Atypical absence seizures (slower $< 2.5\text{ Hz}$ spike-wave, gradual onset/offset), Myoclonic absence seizures, and Juvenile absence epilepsy (lower seizure frequency, higher risk of generalized tonic-clonic seizures).
   • Genetic Metabolic Disorder: GLUT1 Deficiency Syndrome (caused by pathogenic variants in the SLC2A1 gene).
4. Pharmacotherapy:
   • Drug of Choice: Ethosuximide.
     • Mechanism: Blocks low-threshold T-type voltage-gated calcium channels in thalamocortical relay neurons.
     • Dosing: Initial dose $10\text{–}15\text{ mg/kg/day}$ orally in 2 divided doses; titrate weekly by $5\text{ mg/kg/day}$ to a maintenance dose of $20\text{–}40\text{ mg/kg/day}$ (maximum $1500\text{ mg/day}$).
   • Alternative First-Line Agent: Sodium Valproate ($15\text{–}20\text{ mg/kg/day}$ initial, maintenance $20\text{–}40\text{ mg/kg/day}$) — preferred if coexistent generalized tonic-clonic seizures are present.
   • Contraindicated Medications: Carbamazepine, Oxcarbazepine, Phenytoin, or Vigabatrin (these sodium-channel blockers/GABAergic agents exacerbate absence seizures and may precipitate absence status epilepticus).

1. Neuroimaging Protocol:
   • Emergent non-contrast MRI brain including Diffusion-Weighted Imaging (DWI) with Apparent Diffusion Coefficient (ADC) mapping, Fluid-Attenuated Inversion Recovery (FLAIR), and gradient echo/susceptibility-weighted imaging (SWI).
   • Magnetic Resonance Angiography (MRA) of the head and neck (time-of-flight sequences) to evaluate for intracranial arterial stenosis, dissection, or large-vessel cutoff.
2. Etiological Categories and Specific Vasculopathies:
   • Broad Categories:
     • Arteriopathies / Vasculopathies (e.g., focal cerebral arteriopathy, arterial dissection, Moyamoya disease).
     • Cardioembolic disorders (e.g., complex congenital heart disease, infective endocarditis, cardiomyopathy).
     • Systemic and genetic prothrombotic states (thrombophilia).
     • Hematologic / Hemoglobinopathies (e.g., sickle cell disease, severe iron deficiency anemia).
   • Specific Post-Infectious Vasculopathies:
     • Post-varicella arteriopathy (transient cerebral arteriopathy following VZV infection).
     • Focal cerebral arteriopathy of childhood (FCA-I / inflammatory subtype).
3. Prothrombotic and Systemic Workup:
   • Hematology/Biochemistry: Complete blood count with peripheral smear, reticulocyte count, iron studies, ESR, CRP, Hb electrophoresis.
   • Coagulation & Thrombophilia Screen: PT/INR, aPTT, fibrinogen, D-dimer, Antithrombin III activity, Protein C and Protein S functional levels, Factor V Leiden mutation (activated protein C resistance), Prothrombin G20210A mutation, fasting serum homocysteine, and Lipoprotein(a).
   • Autoimmune / Antiphospholipid Screen: Lupus anticoagulant, Anticardiolipin antibodies (IgG/IgM), Anti-$\beta_2$-glycoprotein-I antibodies, and ANA.
   • Cardiac Evaluation: 12-lead ECG and transthoracic/transesophageal echocardiography with bubble study (saline contrast) to exclude intracardiac thrombus, shunt, or vegetations.
4. Acute Medical Management:
   • Neuroprotective Goals:
     • Normoglycemia (target blood glucose $80\text{–}140\text{ mg/dL}$; avoid dextrose-containing hypotonic fluids).
     • Normothermia (maintain core temperature $< 37.5^\circ\text{C}$ with scheduled paracetamol $15\text{ mg/kg/dose}$).
     • Normotension (permissive hypertension: do not lower blood pressure unless systolic BP $> 15\%$ above the 99th percentile for age/sex/height).
     • Maintain normoxia (pulse oximetry $\ge 95\%$).
   • Antithrombotic Therapy:
     • Aspirin: Initial load of $3\text{–}5\text{ mg/kg/day}$ orally once daily (once intracranial hemorrhage is excluded on baseline imaging).
     • Unfractionated heparin or Low-Molecular-Weight Heparin (Enoxaparin $1\text{ mg/kg/dose}$ SC q12h, target anti-Xa level 0.5–1.0 IU/mL) reserved for confirmed arterial dissection or high-risk cardioembolic source.
   • Intravenous Thrombolysis (Alteplase / rtPA):
     • Eligible only under specialized pediatric protocol within a $4.5\text{-hour}$ window from symptom onset if age $\ge 2\text{ years}$, persistent severe neurological deficit (PedNIHSS score $\ge 6$ and $< 25$), radiologically confirmed large-artery occlusion on MRA/CTA, and absence of extensive early ischemic infarction ($> 1/3$ MCA territory) or hemorrhage.
     • Dose: Alteplase $0.9\text{ mg/kg}$ IV (maximum $90\text{ mg}$); $10\%$ administered as an initial IV bolus over 1 minute, followed by the remaining $90\%$ infused over 60 minutes.

flowchart TD
    A[Child with Acute Focal Neurologic Deficit < 4.5 Hours] --> B[Pediatric Stroke Code Activation]
    B --> C[Emergency MRI Brain: DWI, ADC, FLAIR, SWI + MRA Neck/Head]
    C --> D{Intracranial Hemorrhage?}
    D -- Yes --> E[Neurosurgical Consultation & Hemorrhage Protocol]
    D -- No --> F{DWI Confirms Ischemia?}
    F -- No --> G[Investigate Stroke Mimics: Todd Paresis, Hemiplegic Migraine]
    F -- Yes --> H[Arterial Ischemic Stroke Confirmed]
    H --> I{Meets Thrombolysis Criteria? PedNIHSS >= 6, Vessel Occlusion, < 4.5 h}
    I -- Yes --> J[Consider IV Alteplase 0.9 mg/kg in Expert Tertiary Center]
    I -- No --> K[Start Aspirin 3 to 5 mg/kg/day + Strict Neuroprotection]
    K --> L[Comprehensive Workup: Vasculopathy, Cardiac Bubble Echo, Thrombophilia Screen]

1. Primary Diagnosis & Differentials:
   • Primary Category: Congenital Myopathy (structural myopathy).
   • Differential Diagnoses:
     • Spinal Muscular Atrophy (SMA) type 1 (Werdnig-Hoffmann disease)
     • Congenital Muscular Dystrophy (CMD, e.g., Ullrich or Merosin-deficient)
     • Prader-Willi syndrome
     • Congenital Myasthenic Syndromes (CMS)
2. Classical Subtypes:
   • Nemaline (rod) myopathy
   • Central core disease (CCD)
   • Centronuclear / X-linked myotubular myopathy (XLMTM)
3. Histopathology and Genetic Associations:
   • Nemaline Myopathy:
     • Biopsy: Gomori trichrome stain demonstrates clustered subsarcolemmal rod-shaped thread-like structures (nemaline bodies derived from Z-disk material).
     • Gene: NEB (nebulin, autosomal recessive) or ACTA1 (alpha-actin, autosomal dominant/recessive).
   • Central Core Disease:
     • Biopsy: NADH-tetrazolium reductase (NADH-TR) staining reveals well-demarcated rounded, amorphous, pale, central zones devoid of oxidative enzymatic activity running along the length of type 1 fibers.
     • Gene: RYR1 (ryanodine receptor 1, autosomal dominant).
   • X-linked Myotubular Myopathy:
     • Biopsy: Small, rounded muscle fibers with prominent large central nuclei surrounded by a perinuclear halo resembling fetal myotubes (on H&E).
     • Gene: MTM1 (myotubularin, X-linked recessive).
4. Multidisciplinary Management:
   • Respiratory Support: Routine monitoring of forced vital capacity or nocturnal pulse oximetry/capnography; early non-invasive positive pressure ventilation (BiPAP) for nocturnal hypoventilation; cough assist device and prompt airway clearance therapy.
   • Nutrition & Gastrointestinal: Modified feeding techniques, high-calorie formulas; early videofluoroscopic swallowing study (VFSS); placement of gastrostomy tube (G-tube) with or without Nissen fundoplication to prevent aspiration and ensure adequate somatic growth.
   • Orthopedic & Physical Therapy: Surveillance for scoliosis, hip dysplasia, and equinovarus contractures; custom orthoses (AFOs), passive stretching, and physical/occupational therapy.
   • Malignant Hyperthermia (MH) Precautions: Critical for RYR1-related CCD—strict avoidance of volatile inhalational anesthetics (e.g., sevoflurane, isoflurane) and depolarizing muscle relaxants (succinylcholine); availability of IV dantrolene in surgical settings.

1. Diagnosis and Classic Triad:
   • Diagnosis: Congenital Toxoplasmosis (Toxoplasma gondii infection).
   • Classic Sabin Triad:
     • Chorioretinitis
     • Intracranial calcifications
     • Hydrocephalus (obstructive ventriculomegaly)
2. Neuroimaging Distinction:
   • Congenital Toxoplasmosis: Diffuse, scattered parenchymal calcifications involving the cerebral cortex, basal ganglia, and periventricular white matter, accompanied by aqueductal stenosis leading to generalized hydrocephalus.
   • Congenital CMV: Calcifications are predominantly periventricular (subependymal ring pattern lining the ventricles), frequently associated with microcephaly, lissencephaly/pachygyria, and polymicrogyria.
3. Complete 12-Month Pharmacotherapeutic Protocol:
   • Pyrimethamine:
     • Initial loading dose: $2\text{ mg/kg/day}$ PO divided every 12 hours for 2 days.
     • Continuation dose: $1\text{ mg/kg/day}$ PO once daily for 2 to 6 months.
     • Maintenance dose: $1\text{ mg/kg/day}$ PO given 3 days per week (Monday, Wednesday, Friday) to complete a total duration of 12 months.
   • Sulfadiazine:
     • $100\text{ mg/kg/day}$ PO divided into 2 equal doses (every 12 hours) daily for 12 months.
   • Folinic Acid (Leucovorin calcium):
     • $10\text{ mg}$ PO three times weekly administered alongside pyrimethamine to prevent bone marrow toxicity (increased to $20\text{--}50\text{ mg/day}$ if severe neutropenia occurs).
4. Corticosteroids & Monitoring:
   • Indications for Corticosteroids:
     • Active macula-threatening chorioretinitis.
     • Elevated CSF protein $\ge 1\text{ g/dL}$ ($1000\text{ mg/dL}$).
     • Regimen: Prednisolone $1\text{ mg/kg/day}$ PO divided q12h until inflammation subsides or CSF protein drops $< 1\text{ g/dL}$, followed by a gradual taper.
   • Mandatory Monitoring Parameters:
     • Complete Blood Count (CBC) with differential weekly to biweekly (monitor for pyrimethamine-induced neutropenia, anemia, and thrombocytopenia).
     • Serial ophthalmologic examinations and repeat neuroimaging / head circumference tracking for worsening hydrocephalus.

1. Diagnosis & Risk Factors:

   • Diagnosis: Deformational (positional) plagiocephaly (associated with congenital muscular torticollis).
   • Predisposing Risk Factors:
     • Supine sleep positioning ("Back to Sleep" campaign)
     • Prematurity / prolonged NICU stay (softer calvarium, prolonged immobility)
     • Congenital muscular torticollis (restricted cervical range of motion)
     • Male sex
     • Developmental gross motor delay / reduced neck muscle tone

2. Differentiating Positional Plagiocephaly vs Unilateral Lambdoid Synostosis:

   Feature	Deformational Plagiocephaly	Unilateral Lambdoid Synostosis
   Head Shape from Vertex	Parallelogram shape	Trapezoid shape
   Ipsilateral Ear Position	Displaced anteriorly	Displaced posteriorly/inferiorly
   Ipsilateral Forehead	Ipsilateral frontal bossing	Contralateral frontal bossing
   Occiput Contour	Unilateral occipitoparietal flattening	Ridge over fused lambdoid suture

3. Mathematical Derivation of CVAI:
   

   $$ > \begin{aligned} > \text{CVAI} &= \left( \frac{|\text{Diagonal } A - \text{Diagonal } B|}{\text{Greater Diagonal}} \right) \times 100 \\ > &= \left( \frac{|145\text{ mm} - 128\text{ mm}|}{145\text{ mm}} \right) \times 100 \\ > &= \left( \frac{17}{145} \right) \times 100 \\ > &= \mathbf{11.72\%} \quad (\text{Reference: } < 3.5\% \text{ normal; } > 7\% \text{ moderate-to-severe plagiocephaly}) > \end{aligned} > $$

4. Stepped Management Protocol:

   • Physical Therapy: Targeted stretching of the shortened sternocleidomastoid muscle (for torticollis) and active cervical strengthening exercises.
   • Repositioning & Tummy Time: Supervised prone positioning ("tummy time") for $\ge 30\text{--}60\text{ minutes/day}$ during waking hours; alternating cot orientation and head position during sleep.
   • Cranial Remolding Orthosis (Helmet Therapy):
     • Indicated here given infant's age ($> 6\text{--}8\text{ months}$) and moderate-to-severe deformity ($\text{CVAI} = 11.7\% > 7\%$).
     • Must be worn $23\text{ hours/day}$ for a duration of 3 to 5 months, adjusted every 2 to 4 weeks to accommodate cranial growth until fontanel closure / satisfactory symmetry.

1. Normative Milestone Ages:

   Milestone	Normative Age of Attainment
   Follows moving object smoothly through $180^\circ$	2 to 3 months
   Sustained reciprocal social smile, vocalizes to sound/music	3 months
   Unassisted sitting with hands free on floor (tripod sitting)	6 months
   Polysyllabic vowel sounds / babbling ("ba-ba", "da-da" non-specific)	7 to 8 months
   Creeps on hands and knees or crawls	9 to 10 months
   Mature neat pincer grasp (pad of thumb to tip of index finger)	10 to 12 months
   Stands alone independently without support	12 months
   Climbs stairs with two feet per step while holding rail	18 months

2. Developmental Quotient (DQ) Calculation:
   

   $$ > \begin{aligned} > \text{Developmental Quotient (DQ)} &= \left( \frac{\text{Developmental Age (DA)}}{\text{Chronological Age (CA)}} \right) \times 100 \\ > &= \left( \frac{9\text{ months}}{18\text{ months}} \right) \times 100 \\ > &= \mathbf{50\%} \quad (\text{Reference: } > 85\% \text{ normal; } < 70\% \text{ significant delay}) > \end{aligned} > $$

3. Absolute Developmental Red Flags ($\le 12$ months):

   • Failure to fixate and follow visual targets or lack of responsiveness to sound by 3 months.
   • Absence of reciprocal social smile by 2 to 3 months.
   • Persistent fisting of hands beyond 3 months, or hand dominance prior to 12 months (signifies contralateral hemiparesis).
   • Inability to sit without support by 9 months.
   • Absence of babbling, pointing, or communicative gesturing by 12 months.
   • Any loss (regression) of previously acquired motor, language, or social skills at any age.

4. Standardized Screening Tools:

   • Ages and Stages Questionnaires, Third Edition (ASQ-3)
   • Denver Developmental Screening Test II (DDST-II) / Trivandrum Developmental Screening Chart (TDSC)

1. Syndrome, Gene, and Inheritance:
   • Syndrome: Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy - SMEI).
   • Gene: SCN1A (encodes the voltage-gated sodium channel alpha-1 subunit, $\text{Na}_{\text{v}}1.1$).
   • Mode of Inheritance: Autosomal dominant, but $> 90\%$ arise as de novo mutations.
2. Cellular Pathophysiology:
   • Heterozygous loss-of-function mutations in SCN1A cause haploinsufficiency of $\text{Na}_{\text{v}}1.1$ sodium channels.
   • These channels are selectively expressed at high density on the axon initial segments of GABAergic inhibitory interneurons (e.g., parvalbumin-positive basket cells).
   • Reduced functional sodium current impairs the sustained high-frequency action potential firing of inhibitory interneurons without impairing excitatory pyramidal neurons.
   • The resultant disinhibition tips the cortical and hippocampal networks into uncontrolled hyperexcitability and intractable seizures.
3. Recommended Maintenance Therapies:
   • First-line: Clobazam ($0.5\text{--}1.0\text{ mg/kg/day}$ PO divided q12h) and Sodium Valproate ($20\text{--}40\text{ mg/kg/day}$ PO divided q12h).
   • Second-line / Add-on: Stiripentol ($50\text{ mg/kg/day}$ PO divided q8–12h, co-administered with clobazam and valproate).
   • Targeted Novel Therapies: Fenfluramine ($0.2\text{--}0.7\text{ mg/kg/day}$ PO divided q12h, max $26\text{ mg/day}$) or Cannabidiol ($5\text{--}20\text{ mg/kg/day}$ PO divided q12h).
   • Non-pharmacological: Ketogenic Diet (4:1 or 3:1 lipid-to-non-lipid ratio).
4. Strictly Contraindicated Medications:
   • Contraindicated Drugs:
     • Carbamazepine / Oxcarbazepine
     • Phenytoin / Fosphenytoin
     • Lamotrigine
     • Lacosamide
     • Vigabatrin
   • Pharmacodynamic Basis: These agents act primarily as voltage-gated sodium channel blockers. By further blocking the already deficient $\text{Na}_{\text{v}}1.1$ channels on remaining GABAergic interneurons, they exacerbate inhibition failure, provoke status epilepticus, and accelerate cognitive decline.

graph TD
    A[SCN1A Loss-of-Function Mutation] --> B[Haploinsufficiency of Nav1.1 Channels]
    B --> C[Impaired Action Potential Firing in GABAergic Interneurons]
    C --> D[Failure of Cortical and Hippocampal Inhibition]
    D --> E[Diffuse Network Hyperexcitability]
    E --> F[Prolonged Hemiclonic / Febrile Status Epilepticus]
    E --> G[Subsequent Myoclonic & Absence Seizures with Cognitive Stalling]
    H[Sodium Channel Blockers: Phenytoin, Carbamazepine, Lamotrigine] -.->|Worsens Blockade| B

Early genetic diagnosis is critical to avoid sodium channel blockers and initiate targeted combinations (valproate, clobazam, stiripentol, fenfluramine) alongside an aggressive fever-control and emergency seizure-rescue protocol.

1. Diagnosis and Inheritance:
   • Diagnosis: Duchenne Muscular Dystrophy (DMD).
   • Mode of Inheritance: X-linked recessive (mutation in the DMD gene located on chromosome Xp21.2 encoding dystrophin).
2. Molecular Diagnostic Protocol:
   • First-line: Multiplex Ligation-dependent Probe Amplification (MLPA) or chromosomal microarray of the DMD gene to detect copy number variations (large multiexon deletions account for 65–70%, and duplications account for 5–10% of cases).
   • Second-line (Reflex): If MLPA is negative, perform Next-Generation Sequencing (NGS) with targeted DMD gene sequencing to identify small point mutations (nonsense, frameshift, splice-site), followed by Sanger verification (accounts for 20–25% of cases).
3. Mathematical Derivation of Genetic Risk:
   $$ > \begin{aligned} > \text{P}(\text{Mother of proband is carrier}) &= \frac{2}{3} \quad (\text{Haldane's Rule for simplex X-linked lethal trait}) \\ > \text{P}(\text{Patient is carrier}) &= \text{P}(\text{Mother is carrier}) \times \text{P}(\text{Transmission}) \\ > &= \frac{2}{3} \times \frac{1}{2} = \mathbf{\frac{1}{3} \quad (33.3\%)} \\ > \text{P}(\text{Male fetus affected}) &= \text{P}(\text{Patient is carrier}) \times \text{P}(\text{Transmitting mutant allele to male}) \\ > &= \frac{1}{3} \times \frac{1}{2} = \mathbf{\frac{1}{6} \quad (16.7\%)} > \end{aligned} > $$
4. Prenatal Diagnostic Strategy:
   • Fetal Sex Determination: Non-invasive prenatal testing (NIPT) utilizing cell-free fetal DNA (cffDNA) in maternal plasma to determine fetal sex. If female, invasive testing may be deferred (except to exclude rare manifest carrier states/Turner mosaicism).
   • Definitive Invasive Testing:
     • At present gestational age (18 weeks): Transabdominal amniocentesis (15–20 weeks) to retrieve fetal amniocytes for targeted MLPA/sequencing matching the index familial mutation.
     • If presenting earlier in future pregnancies: Chorionic villus sampling (CVS) at 11–13 weeks.

graph TD
    A[Simplex Male Proband with DMD] --> B{Haldane Rule: 1/3 New Mutation, 2/3 Carrier Mother}
    B --> C[Mother Carrier Probability: 66.7%]
    C --> D[Sister Carrier Probability: 33.3%]
    D --> E{Fetal Sex via Maternal cffDNA}
    E -->|Female Fetus| F[Risk of Clinical DMD: Near Zero]
    E -->|Male Fetus| G[Risk of DMD: 1/3 x 1/2 = 16.7%]
    G --> H[Amniocentesis at 15-20 wk for Targeted Molecular Analysis]

1. Neuroimaging Findings & Diagnosis:
   • Findings: Well-demarcated, hyperdense, biconvex (lentiform), extra-axial collection along the left temporoparietal convexity exerting significant mass effect, partial effacement of the left lateral ventricle, and midline shift. The collection does not cross cranial suture lines.
   • Diagnosis: Acute Extradural Hematoma (Epidural Hematoma, EDH).
2. Anatomical Source & Fracture Location:
   • Vascular Source: Laceration of the Middle Meningeal Artery (MMA) or its anterior branch (or less commonly middle meningeal vein or diploic veins).
   • Fracture Location: Squamous temporal bone fracture traversing the pterion / groove for the middle meningeal vessels.
3. Distinguishing Features: EDH vs. Acute SDH:
   • Shape: EDH is biconvex/lenticular; acute SDH is crescentic (concavoconvex) tracking along the cerebral hemisphere.
   • Suture Line Boundaries: EDH is restricted by cranial sutures (where dura attaches firmly to periosteum); acute SDH crosses suture lines and is restricted only by dural reflections (falx cerebri and tentorium cerebelli).
   • Pathophysiology/Vascular Origin: EDH is predominantly arterial (high-pressure MMA laceration); acute SDH is predominantly venous (shearing of bridging cortical veins across the subdural space).
4. Surgical Indications and Osmotherapy Dosing:
   • Neurosurgical Indications (Brain Trauma Foundation Guidelines):
     • Hematoma volume $> 30\text{ cm}^3$ regardless of GCS score.
     • GCS score $< 9$ with pupillary asymmetry, anisocoria $> 2\text{ mm}$, or fixed dilated pupil.
     • Thickness $> 15\text{ mm}$ or midline shift $> 5\text{ mm}$ on cranial CT.
   • Emergency Osmotherapy Calculation (3% Hypertonic Saline):
     $$ > \begin{aligned} > \text{Dose Range} &= 3\text{ to }5\text{ mL/kg IV bolus over }10\text{--}20\text{ minutes} \\ > \text{Calculated Volume} &= 30\text{ kg} \times 3\text{ to }5\text{ mL/kg} \\ > &= \mathbf{90\text{ to }150\text{ mL IV of 3\% NaCl}} > \end{aligned} > $$

1. Classification and Defining Criteria:
   • Classification: Simple (Typical) Febrile Seizure.
   • Four Core Criteria:
     • Primary generalized seizure without focal onset or post-ictal focal deficit (e.g., Todd paresis).
     • Duration $< 15$ minutes.
     • Occurs as a single solitary episode within a 24-hour period.
     • Occurs in a neurologically normal child aged 6 to 60 months without evidence of intracranial infection or metabolic disturbance.
2. Indications for Lumbar Puncture:
   • Clinical signs of meningeal irritation (neck stiffness, Kernig sign, Brudzinski sign) or bulging fontanelle.
   • Persistent post-ictal altered mental status, excessive lethargy, or signs of encephalopathy.
   • Infants $< 6$ months of age presenting with fever and seizure.
   • Strongly consider in infants aged 6 to 12 months who are unimmunized or incompletely immunized against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae, or when clinical assessment is obscured by pre-hospital antibiotics.
   • Complex febrile status epilepticus.
3. Recurrence Risk & Risk Factors:
   • Baseline Recurrence Risk: Approximately $30\text{--}35\%$ overall after a first episode ($50\%$ if onset is $< 12$ months).
   • Four Major Recurrence Risk Factors:
     • Age of onset $< 18$ months.
     • Low peak temperature at the time of seizure onset ($< 38.5^\circ\text{C}$).
     • Short duration of recognized fever prior to convulsion ($< 1$ hour).
     • Family history of febrile seizures in a first-degree relative.
4. Acute Abortive Pharmacology:
   • Drug & Route: Intranasal Midazolam (1st line needle-free) OR Rectal Diazepam.
   • Weight-based Dosing (for 11-kg child):
     • Intranasal Midazolam: $0.2\text{ mg/kg/dose}$ ($11\text{ kg} \times 0.2\text{ mg/kg} = \mathbf{2.2\text{ mg}}$ intranasally; administer $0.44\text{ mL}$ of $5\text{ mg/mL}$ solution using an atomization device).
     • Rectal Diazepam: $0.3\text{ to }0.5\text{ mg/kg/dose}$ ($11\text{ kg} \times 0.3\text{--}0.5\text{ mg/kg} = \mathbf{3.3\text{ to }5.5\text{ mg}}$ rectally).

1. Diagnosis, Gene, and Molecular Defect:
   • Diagnosis: Friedreich Ataxia (FRDA).
   • Gene & Locus: FXN gene on chromosome 9q21.11 encoding the mitochondrial protein frataxin.
   • Molecular Defect: Homozygous GAA trinucleotide repeat expansion in intron 1 of the FXN gene (normal: 5–33 repeats; pathogenic: 66 to $> 1000$ repeats).
2. Neuroanatomical Localization of Discrepant Reflexes:
   • Absent Deep Tendon Reflexes: Degeneration of the primary sensory neurons in the dorsal root ganglia (DRG) and their large myelinated afferents (group Ia fibers), leading to disruption of the afferent limb of the monosynaptic stretch reflex arc.
   • Extensor Plantar Responses (Babinski Sign): Concomitant degeneration of the upper motor neuron pathways within the lateral corticospinal tracts of the spinal cord.
3. Extra-Neurological Manifestations:
   • Cardiovascular: Hypertrophic cardiomyopathy (concentric left ventricular hypertrophy), rhythm disturbances (supraventricular arrhythmias), and congestive heart failure.
   • Endocrine: Impaired glucose tolerance and Diabetes Mellitus (secondary to mitochondrial iron-induced oxidative damage to pancreatic beta cells).
   • Orthopedic / Musculoskeletal: Progressive kyphoscoliosis, pes cavus, and hammer toe deformities.
4. Disease-Modifying Pharmacotherapy:
   • Drug: Omaveloxolone (FDA-approved for patients $\ge 16$ years of age).
   • Mechanism: Nuclear factor erythroid 2-related factor 2 (Nrf2) activator. It restores cellular redox homeostasis, attenuates mitochondrial oxidative stress, and reverses bioenergetic deficiency caused by frataxin depletion.

1. Metabolic Diagnosis:
   • Disorder: Glutaric Aciduria Type 1 (GA-1 / Glutaric Acidemia Type 1).
   • Deficient Enzyme: Glutaryl-CoA dehydrogenase (GCDH).
   • Gene: GCDH gene on chromosome 19p13.2 (Autosomal recessive).
2. Neuroimaging Sign and Diagnostic Pitfall:
   • Neuroimaging Term: "Batwing" appearance of the Sylvian fissures (secondary to frontotemporal atrophy with widened Sylvian fissures and open opercula exposing the insulae).
   • Diagnostic Pitfall: The presence of subdural hygromas or hematomas (resulting from stretching and rupture of bridging veins across the enlarged extra-axial space) combined with retinal hemorrhages and macrocephaly is frequently misdiagnosed as non-accidental trauma (abusive head trauma / shaken baby syndrome).
3. Confirmatory Biochemical Profile:
   • Urine Organic Acid Analysis (GC-MS): Marked elevation of glutaric acid and 3-hydroxyglutaric acid (note: "low excretor" phenotypes may demonstrate only trace glutaric acid; 3-hydroxyglutaric acid is the more reliable diagnostic hallmark).
   • Plasma Acylcarnitine Profile (TMS): Elevated glutarylcarnitine (C5DC acylcarnitine).
4. Emergency Resuscitation Regimen (8-kg Infant):
   • Cessation of Protein Intake: Complete cessation of natural protein/lysine intake for 24 to 48 hours to halt generation of toxic neuro-metabolites.

1. Differentiating Checklist (Gray vs White Matter Disease):
   • Dementia / Cognitive decline: Early and prominent in gray matter disease; late in white matter disease.
   • Seizures / Epilepsy: Early, frequent, refractory, and often myoclonic in gray matter disease; rare or late-onset in white matter disease.
   • Motor signs (Tone / Weakness): Gray matter presents with hypotonia or normal tone early, progressing to variable spasticity late; white matter presents early with upper motor neuron signs (spasticity, hyperreflexia, extensor plantars) and early motor regression.
   • Involuntary movements: Choreoathetosis, dystonia, and myoclonus are prominent and early in gray matter; rare in white matter (ataxia may be early in specific leukodystrophies).
   • Peripheral neuropathy: Absent in pure gray matter disease; frequently present early in specific white matter diseases (e.g., Metachromatic leukodystrophy, Krabbe disease).
   • Visual involvement: Early retinal involvement (macular cherry-red spot, pigmentary retinopathy) in gray matter; optic atrophy or cortical blindness typically late in gray matter, but early optic atrophy occurs in white matter disease.
2. Representative Disorders:
   • Primary Gray Matter: Neuronal Ceroid Lipofuscinosis (Batten disease), GM2 gangliosidosis (Tay-Sachs disease), Alpers-Huttenlocher syndrome, Gaucher disease type 2/3.
   • Primary White Matter: Metachromatic leukodystrophy (arylsulfatase A deficiency), Krabbe disease (globoid cell leukodystrophy), X-linked adrenoleukodystrophy (X-ALD), Canavan disease.
3. Neurodiagnostic Modalities (EEG & MRI):
   • EEG Findings:
     • Gray matter: Severe early abnormalities, including diffuse background slowing, continuous epileptiform discharges, burst-suppression, and progressive photoparoxysmal response (e.g., low-frequency photic stimulation in late-infantile NCL).
     • White matter: Normal or mild non-specific slowing until terminal stages of disease.
   • Brain MRI Findings:
     • Gray matter: Progressive diffuse cortical cerebral atrophy, basal ganglia/thalamic signal alteration or volume loss, with relative preservation of deep white matter bulk early.
     • White matter: Diffuse, confluent, symmetrical T2/FLAIR hyperintensity in cerebral white matter, often sparing subcortical U-fibers early, with delayed or dysmyelinating patterns.
4. Ophthalmologic Manifestations:
   • Gray Matter Disease: Retinal storage pathology produces a cherry-red spot at the macula (Tay-Sachs, Niemann-Pick type A), progressive retinitis pigmentosa / pigmentary retinopathy (NCL, mitochondrial encephalopathies), and tapetoretinal degeneration.
   • White Matter Disease: Primary optic atrophy (early in Krabbe disease and X-ALD); retinal cherry-red spots and pigmentary changes are classically absent (except in peroxisomal assembly disorders like Zellweger spectrum).

1. Diagnosis & Etiology:
   • Diagnosis: Guillain-Barré Syndrome (GBS) / Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP).
   • Pathogen: Campylobacter jejuni (molecular mimicry via ganglioside GM1/GD1a autoantibodies).
2. CSF Abnormality & Timing:
   • Albuminocytological Dissociation: Marked elevation in CSF protein level ($>45\text{ mg/dL}$, often $>100\text{ mg/dL}$) with a normal CSF white cell count ($<10\text{ mononuclear cells/mm}^3$).
   • Timing: Most prominent during the 2nd to 3rd week after symptom onset (may be normal in up to 50% of patients during the first 48–72 hours).
3. Electrodiagnostic Differentiation (AIDP vs AMAN):
   • AIDP (Demyelinating):
     • Prolongation of distal motor latencies (DML $>130\%$ of upper limit).
     • Marked slowing of motor nerve conduction velocities (NCV $<70-80\%$ of lower limit).
     • Conduction blocks and abnormal temporal dispersion.
     • Prolonged or absent F-wave latencies.
   • AMAN (Axonal):
     • Significant reduction in Compound Muscle Action Potential (CMAP) amplitudes ($<80\%$ of lower limit) with preserved sensory nerve action potentials (SNAPs).
     • Conduction velocities and distal latencies remain normal or only minimally delayed ($>80\%$ of normal).
     • Absence of demyelinating features (no conduction block or temporal dispersion).
4. Management & Monitoring:
   • Immunomodulatory Therapy:
     • Intravenous Immunoglobulin (IVIg): $2\text{ g/kg}$ total dose administered intravenously, divided either as $0.4\text{ g/kg/day}$ for 5 consecutive days or $1\text{ g/kg/day}$ for 2 consecutive days.
     • Alternative: Therapeutic Plasma Exchange (TPE / Plasmapheresis) at $200\text{--}250\text{ mL/kg}$ total exchange volume divided over 4 to 5 sessions on alternate days.
   • Bedside Respiratory Monitoring:
     • Forced Vital Capacity (FVC): Serial measurement; values $<15\text{--}20\text{ mL/kg}$ warrant elective endotracheal intubation.
     • Single Breath Count (SBC): Serial test; count $<15\text{--}20$ on a single resting breath indicates diaphragmatic compromise.
     • Negative Inspiratory Force (NIF): Values weaker than $-20\text{ to }-30\text{ cm H}_2\text{O}$.

1. Prognostic Significance of Seizure Timing:
   • Early Seizures ($<48\text{ hours}$): Seen in $20\text{--}30\%$ of bacterial meningitis cases; secondary to high-grade fever, acute toxic encephalopathy, localized cerebral edema, or transient hyponatremia (SIADH). When prompt metabolic and seizure stabilization is achieved, early seizures do not independently herald permanent long-term neurodevelopmental impairment.
   • Late-Onset Seizures ($>\text{Day } 4$ of therapy) or Focal Seizures: Highly ominous; indicates localized parenchymal injury such as cerebral cortical infarction, septic dural venous sinus thrombosis, cerebritis/abscess, subdural empyema, ventriculitis, or developing communicating/obstructive hydrocephalus. Correlates strongly with persistent motor deficits, intellectual disability, and secondary epilepsy.
2. Suspected Intracranial Complications:
   • Subdural effusion or subdural empyema.
   • Cerebral cortical infarction secondary to septic thrombophlebitis or arteritis.
   • Ventriculitis with secondary obstructive or communicating hydrocephalus.
   • Brain abscess or focal cerebritis.
3. Imaging Finding & Interventional Indications:
   • Finding: Subdural Effusion (crescentic, extra-axial fluid collection in the frontoparietal subdural space).
   • Indications for Subdural Tap / Surgical Evacuation:
     • Clinical signs of elevated intracranial pressure or impending herniation (persistent vomiting, bradycardia, hypertension, pupillary changes).
     • Persistent focal neurological deficits or intractable focal seizures refractory to anticonvulsants.
     • Evidence of bacterial contamination/infection of the collection (subdural empyema evidenced by persistent fever, ring-enhancement on contrast CT/MRI, or purulence on tap).
     • Progressive rapid macrocephaly with marked midline shift.
     • Note: Asymptomatic sterile effusions resolve spontaneously and require conservative observation.
4. Definitive Treatment Protocol:
   • Antibiotic Regimen:
     • Ceftriaxone: $100\text{ mg/kg/day}$ IV divided every 12 hours (or Cefotaxime: $200\text{--}300\text{ mg/kg/day}$ IV divided every 6 hours).
     • Duration: 10 to 14 days of parenteral therapy for uncomplicated H. influenzae type b meningitis.
   • Adjunctive Corticosteroid:
     • Dexamethasone: $0.15\text{ mg/kg/dose}$ IV every 6 hours ($0.6\text{ mg/kg/day}$) for 2 to 4 days.
     • Administration Window: Must be administered before or concurrently with the first dose of parenteral antibiotics (ineffective if given $>1\text{ hour}$ after antibiotics) to reduce the risk of sensorineural hearing loss.

1. Diagnosis & Diagnostic Framework:
   • Diagnosis: Idiopathic Intracranial Hypertension (IIH) / Pediatric Pseudotumor Cerebri Syndrome (PTCS).
   • Diagnostic Criteria: Modified Friedman Criteria (or Modified Dandy Criteria).
2. Neuroimaging Features (Brain MRI and MRV):
   • Empty or partially empty sella turcica (flattening of pituitary gland).
   • Flattening of the posterior sclera / globe contour.
   • Distension / enlargement of the perioptic subarachnoid space with or without optic nerve sheath tortuosity and intraocular protrusion of the optic nerve head.
   • Bilateral transverse cerebral venous sinus stenosis / collapse on MR venography.
   • Crucial negative: Normal brain parenchyma without space-occupying lesions, hydrocephalus, or dural sinus thrombosis.
3. CSF Manometric & Cytochemical Parameters:
   • CSF Opening Pressure Threshold:
     • $>25\text{ cm H}_2\text{O}$ (or $>250\text{ mm H}_2\text{O}$) in non-sedated, non-obese pediatric patients.
     • $>28\text{ cm H}_2\text{O}$ in children who are

1. Diagnosis and Molecular Genetics:

   • Diagnosis: Incontinentia pigmenti (Bloch–Sulzberger syndrome / Melanoblastosis cutis).
   • Gene: IKBKG (Inhibitor of Kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase Gamma; formerly known as NEMO [Nuclear Factor-$\kappa$B Essential Modulator]).
   • Chromosomal Locus: Xq28.
   • Common Mutation: Deletion of exons 4 through 10 of the IKBKG gene (accounts for ~80% of pathogenic alleles).

2. Mode of Inheritance and Male Lethality:

   • Inheritance: X-linked dominant.
   • Male Lethality: IKBKG encodes an essential regulatory subunit of the I$\kappa$B kinase (IKK) complex necessary for canonical NF-$\kappa$B activation. Complete loss of function abolishes NF-$\kappa$B signaling, rendering hemizygous ($46,XY$) male embryonic cells hypersensitive to Tumor Necrosis Factor-alpha (TNF-$\alpha$)-induced apoptosis, leading to massive embryonic cell death and spontaneous miscarriage during the first or second trimester.
   • Exceptions in Surviving Males: Hemizygous males survive only in the setting of somatic mosaicism (postzygotic mutation) or concurrent $47,XXY$ Klinefelter syndrome. Females survive due to functional mosaicism mediated by X-chromosome inactivation (Lyonization).

3. Chronological Cutaneous Stages:

   • Stage 1 (Vesicular / Inflammatory):
     • Timeline: Birth to first 2–4 months of life.
     • Morphology: Linear erythematous crops of vesicles, pustules, and bullae tracking along the lines of Blaschko (predominantly extremities and trunk), accompanied by marked tissue and peripheral blood eosinophilia.
   • Stage 2 (Verrucous / Hyperkeratotic):
     • Timeline: Age 2–6 months (often overlaps with Stage 1).
     • Morphology: Hyperkeratotic, warty, verrucous papules and plaques arranged linearly, typically on distal extremities and digits.
   • Stage 3 (Hyperpigmented):
     • Timeline: Age 3–6 months persisting into late childhood or adolescence.
     • Morphology: Striking marble-cake, reticular, or swirling whorls of slate-grey to dark brown macular hyperpigmentation along Blaschko lines, most prominent on the trunk and flexures (independent of the prior distribution of Stage 1/2 lesions).
   • Stage 4 (Atrophic / Hypopigmented):
     • Timeline: Adolescence into adulthood.
     • Morphology: Pale, hairless, hypopigmented atrophic linear streaks or patches, often with absence of sweat glands (anhidrosis), classically on the posterior calves and flexor surfaces.

4. Neuro-Ophthalmologic Spectrum and Surveillance Protocol:

   • Central Nervous System Manifestations:
     • Neonatal/infantile encephalopathy and seizures (focal motor, infantile epileptic spasms, or status epilepticus).
     • Cerebral ischemic stroke / occlusive cerebral microangiopathy (involving the deep white matter and corpus callosum).
     • Developmental delay, intellectual disability, microcephaly, and spastic hemiparesis or diplegia.
   • Ophthalmologic Manifestations:
     • Retinal vascular occlusive disease resulting in peripheral retinal ischemia and non-perfusion.
     • Secondary retinal neovascularization, pre-retinal fibrovascular proliferation, tractional or exudative retinal detachment, and vitreous hemorrhage.
     • Strabismus, nystagmus, cataract, and optic nerve atrophy.
   • Retinal Surveillance Protocol:
     • Dilated indirect ophthalmoscopy with scleral indentation immediately at birth or time of diagnosis.
     • Screen monthly until 4 months of age; every 3 months until 12 months; every 6 months until age 3 years; annually thereafter until age 8–10 years.
     • Prompt retinal laser photocoagulation or intravitreal anti-VEGF therapy for areas of peripheral retinal avascularity/neovascularization to prevent detachment.

IKBKG / NEMO Loss of Function (Xq28)
               │
   Defective Canonical NF-κB Activation
               │
┌──────────────┴──────────────┐
▼                             ▼
Hemizygous (XY) Males         Heterozygous (XX) Females
(Complete absence of NEMO)    (Lyonization: Mosaic population of normal & mutant cells)
│                             │
Massive Apoptosis via TNF-α   Immune Activation & Apoptosis of Mutant Clones
│                             │
Early In Utero Lethality      Evolving 4-Stage Blaschkoid Skin Lesions
(Miscarriage in Weeks 8-12)   + Ischemic Microvasculopathy (CNS / Retina)

In heterozygous females, cells expressing the mutant X chromosome trigger an inflammatory cascade characterized by excessive eotaxin release and eosinophilic infiltration (Stage 1). Over time, mutant cutaneous cells undergo programmed cell death and are replaced by cells expressing the normal X chromosome, leading to the clinical resolution of hyperpigmentation and eventual residual atrophy (Stage 4). In the brain and retina, vaso-occlusive endothelial injury leads to ischemic infarctions and subsequent neovascularization.

1. Clinical and Imaging Signs:
   • Clinical sign: Setting-sun phenomenon (downward tonic deviation of the eyeballs with exposure of the sclera between the upper eyelid and the limbus, caused by elevated intracranial pressure impinging on the midbrain tectum and periaqueductal gray matter).
   • Neuroimaging sign: Triventricular/tetraventricular ventriculomegaly with blunting of the frontal horns and periventricular hypoattenuation (transependymal CSF transudation).
2. Motor Examination Findings:
   • Spasticity (hypertonia) manifesting as clasp-knife rigidity, affecting lower limbs significantly more than upper limbs.
   • Bilateral hyperreflexia (brisk knee and ankle jerks), sustained ankle clonus, and persistent extensor plantar responses (Babinski sign).
   • Scissoring of lower extremities on vertical suspension.
3. Neuroanatomical Pathophysiology:
   • Corticospinal tract fibers innervating the lower extremities originate from the paracentral lobule on the medial cortex and traverse the periventricular white matter in close proximity to the margins of the expanding lateral ventricles.
   • Ventricular enlargement causes excessive stretching, elongation, and microvascular ischemia of these periventricular pyramidal fibers, resulting in spastic diplegia with lower extremities affected far more than upper extremities.
4. Definitive Surgery and Temporizing Medical Therapy:
   • Definitive Surgical Options:
     • Ventriculoperitoneal (VP) shunt placement with a pressure-regulated valve.
     • Endoscopic Third Ventriculostomy (ETV) with or without Choroid Plexus Cauterization (CPC) for obstructive etiology (e.g., aqueductal stenosis).
   • Acute Temporizing Pharmacotherapy:
     • Acetazolamide: Carbonic anhydrase inhibitor reducing CSF formation at the choroid plexus; Dose: $25\text{ to }100\text{ mg/kg/day}$ PO divided every 6 to 8 hours.
     • Furosemide: Loop diuretic providing synergistic decrease in CSF synthesis; Dose: $1\text{ mg/kg/dose}$ IV or PO every 12 hours.

flowchart TD
    A[Impaired CSF Resorption / Outflow Obstruction] --> B[Progressive Ventriculomegaly]
    B --> C[Elevated Intracranial Pressure]
    C --> D[Compression of Midbrain Tectum]
    D --> E[Setting-Sun Sign / Parinaud-like Paresis]
    B --> F[Mechanical Stretch of Periventricular Corticospinal Tracts]
    F --> G[Selective Lower Limb Spasticity & Hyperreflexia]

1. Clinical Diagnosis:
   • Infantile Tremor Syndrome (ITS) / Nutritional Tremor Syndrome secondary to severe maternal and infantile nutritional Vitamin $\text{B}_{12}$ (Cobalamin) deficiency.
2. Cutaneous Finding:
   • Knuckle hyperpigmentation (confluent, dark, symmetric hyperpigmentation over the dorsal aspect of distal and proximal interphalangeal joints and metacarpophalangeal joints).
3. Laboratory and Smear Findings:
   • Complete Blood Count / Smear: Severe macrocytic anemia with elevated mean corpuscular volume ($\text{MCV} > 100\text{ fL}$), macro-ovalocytes, anisopoikilocytosis, hypersegmented neutrophils ($\ge 5$ lobes in $>5\%$ of cells or a single neutrophil with $\ge 6$ lobes), and mild bicytopenia/pancytopenia with reticulocytopenia.
   • Biochemistry: Markedly reduced serum Vitamin $\text{B}_{12}$ levels ($< 100\text{ pg/mL}$), markedly elevated serum homocysteine, and elevated urine/serum methylmalonic acid (MMA).
4. Management Protocol:
   • Vitamin $\text{B}_{12}$ Replacement:
     • Cyanocobalamin or Methylcobalamin: $100\text{ to }1000\ \mu\text{g}$ intramuscularly (IM) daily for 7 to 14 days, followed by $100\ \mu\text{g}$ IM weekly for 4 weeks, and then maintenance monthly until complete nutritional rehabilitation.
     • Oral Folic acid ($1\text{ mg/day}$) and elemental Iron ($3\text{ mg/kg/day}$) must be co-administered, but folic acid must never be administered alone prior to initiating cobalamin (prevents precipitation of subacute combined degeneration).
   • Symptomatic Management of Coarse Tremors:
     • Tremors typically transiently worsen 48–72 hours after starting cobalamin therapy.
     • Propranolol: $1\text{ to }2\text{ mg/kg/day}$ PO divided every 8 to 12 hours, OR
     • Phenobarbital: $3\text{ to }5\text{ mg/kg/day}$ PO divided every 12 hours for 1 to 2 weeks, then tapered.

1. Diagnostic Tests:
   • Repetitive Nerve Stimulation (RNS): Decremental response of greater than $10\%$ in the compound muscle action potential (CMAP) amplitude between the 1st and the 4th or 5th stimulus delivered at low frequencies ($2\text{ to }3\text{ Hz}$).
   • Bedside Test: Ice Pack Test (application of an ice-filled glove or ice pack over the closed ptotic eyelid for 2 minutes; a positive result is an improvement/widening of the palpebral fissure width by $\ge 2\text{ mm}$).
2. Mediastinal Pathology and Imaging:
   • Pathology: Thymic hyperplasia (seen in $65\text{–}75\%$ of pediatric cases) or Thymoma (rare in young children, $<5\%$).
   • Imaging: Contrast-enhanced Computed Tomography (CECT) of the chest or anterior mediastinal Magnetic Resonance Imaging (MRI).
3. First-Line Pharmacotherapy:
   • Drug: Pyridostigmine bromide (acetylcholinesterase inhibitor).
   • Dosing: Initial dose of $0.5\text{ to }1.0\text{ mg/kg/dose}$ orally administered every 4 to 6 hours; titrate gradually up to a maximum of $7\text{ mg/kg/day}$ (or maximum $300\text{ mg/day}$).
   • Timing: Administer 30 to 45 minutes prior to meals to maximize chewing and swallowing strength.
4. Exacerbating Antimicrobial Classes:
   • Aminoglycosides (e.g., Gentamicin, Amikacin, Tobramycin) — inhibit presynaptic acetylcholine release and reduce postsynaptic sensitivity.
   • Fluoroquinolones (e.g., Ciprofloxacin, Levofloxacin) — augment neuromuscular transmission failure; carries a black-box warning.
   • Macrolides / Ketolides (e.g., Azithromycin, Erythromycin, Telithromycin).

1. Definition and Absolute Contraindications:
   • Macronutrient Ratio: A ratio of $4:1$ (or $3:1$) by weight of dietary fat to combined non-fat nutrients (carbohydrates plus proteins), meaning $4\text{ grams}$ of fat for every $1\text{ gram}$ of combined carbohydrate and protein.
   • Absolute Contraindications:
     • Primary carnitine deficiency.
     • Carnitine palmitoyltransferase (CPT) I or II deficiency.
     • Carnitine-acylcarnitine translocase (CACT) deficiency.
     • Mitochondrial fatty acid $\beta$-oxidation defects (SCAD, MCAD, LCAD, VLCAD).
     • Pyruvate carboxylase deficiency.
2. Target Neurometabolic Disorders:
   • Glucose Transporter Protein 1 (GLUT-1) Deficiency Syndrome (mutations in SLC2A1).
   • Pyruvate Dehydrogenase Complex (PDHC) Deficiency.
3. Mathematical Derivation of Dietary Fat:
   • In a $4:1$ classic ketogenic diet, each unit consists of $4\text{ g}$ of fat ($9\text{ kcal/g}$) and $1\text{ g}$ of combined carbohydrate/protein ($4\text{ kcal/g}$).
     $$ > \begin{aligned} > \text{Energy per diet unit} &= (4\text{ g} \times 9\text{ kcal/g}) + (1\text{ g} \times 4\text{ kcal/g}) \\ > &= 36\text{ kcal} + 4\text{ kcal} = \mathbf{40\text{ kcal/unit}} \\ > \text{Total diet units/day} &= \frac{1200\text{ kcal/day}}{40\text{ kcal/unit}} = \mathbf{30\text{ units/day}} \\ > \text{Total daily fat requirement} &= 30\text{ units} \times 4\text{ g fat/unit} \\ > &= \mathbf{120\text{ g of fat/day}} > \end{aligned} > $$
4. Complications:
   • Acute Complications: Symptomatic hypoglycemia (blood glucose $<40\text{ mg/dL}$), severe metabolic acidosis / uncompensated ketosis, dehydration, persistent vomiting, somnolence.
   • Long-term Complications: Nephrolithiasis (calcium oxalate and uric acid renal calculi), dyslipidemia (hypercholesterolemia, elevated LDL/triglycerides), linear growth impairment/stunting, osteopenia/fractures, prolonged QTc interval / cardiomyopathy (due to selenium deficiency).

1. Diagnosis and Cardinal Deficit:
   • Diagnosis: Landau-Kleffner Syndrome (LKS) / Acquired Epileptic Aphasia.
   • Cardinal Deficit: Auditory verbal agnosia ("word deafness") — inability to decode, process, and comprehend spoken language despite intact peripheral hearing and preservation of response to environmental, non-verbal auditory cues.
2. Electrophysiological Confirmation:
   • Investigation: Overnight continuous sleep electroencephalography (Sleep EEG / Video-EEG monitoring).
   • Hallmark Finding: Electrical Status Epilepticus in Sleep (ESES) / Continuous Spike-and-Wave during slow-wave Sleep (CSWS), characterized by continuous or near-continuous ($>85\%$, or at minimum $>50\%$) bilateral or temporal-parietal-predominant spike-wave discharges occupying the duration of non-REM (slow-wave) sleep.
3. Differentiation from Autism Spectrum Disorder (ASD):
   • Premorbid Development and Age of Onset: Children with LKS exhibit entirely normal developmental and language acquisition milestones until 3 to 7 years of age before acute/subacute language regression, whereas ASD presents before 3 years of age with early sociocommunicative and reciprocal interaction impairments.
   • Non-Verbal Intelligence & Social Reciprocity: Non-verbal communicative intent, eye contact, and non-verbal IQ are preserved in LKS (patients readily adopt pantomime and visual sign languages), unlike the pervasive impairment of social reciprocity and repetitive/stereotyped behaviors characteristic of ASD.
4. Acute Pharmacotherapy Protocol:
   • First-Line Corticosteroid Therapy:
     • Intravenous Methylprednisolone: $30\text{ mg/kg/day}$ (maximum $1000\text{ mg/day}$) IV infused over 2 hours daily for 3 consecutive days each month, OR
     • Oral Prednisolone: $2\text{ mg/kg/day}$ (up to $60\text{ mg/day}$) orally for 1 to 3 months, followed by slow, vigilant taper over 6 to 12 months.
   • Anti-Seizure Medications for CSWS:
     • High-dose Clobazam: $0.5\text{ to }1.0\text{ mg/kg/day}$ PO, OR
     • Sodium Valproate: $20\text{ to }40\text{ mg/kg/day}$ PO, OR Ethosuximide: $20\text{ to }40\text{ mg/kg/day}$ PO.
     • Caution: Phenytoin, Carbamazepine, Oxcarbazepine, and Vigabatrin are strictly avoided as they potentiate and exacerbate CSWS.

1. Most Likely Diagnosis:
   • Leigh syndrome (Subacute Necrotizing Encephalomyelopathy).
2. Characteristic Magnetic Resonance Spectroscopy ($^1\text{H}$-MRS) Finding:
   • Inverted doublet peak of lactate at 1.33 ppm on intermediate/long echo time (TE 135–288 ms) sequences within the affected basal ganglia and normal-appearing brain parenchyma.
   • Prominent lactate singlet peak at 1.33 ppm on short echo time (TE 30–35 ms).
   • Associated reduction of the N-acetylaspartate (NAA) peak at 2.0 ppm (reflecting neuronal loss/dysfunction) and elevated choline peak at 3.2 ppm.
3. Confirmatory Genetic and Biochemical Strategy:
   • Biochemical Testing:
     • Paired plasma and CSF lactate and pyruvate: elevated CSF lactate (>2.0 mmol/L) and elevated lactate-to-pyruvate ratio (>20 indicates respiratory chain defect; <10 suggests pyruvate dehydrogenase deficiency).
     • Plasma amino acids (elevated alanine) and urinary organic acids (elevated lactate, pyruvate, and tricarboxylic acid cycle intermediates).
   • Genetic Testing:
     • Simultaneous mitochondrial DNA (mtDNA) sequencing (e.g., MT-ATP6, MT-TL1, MT-ND genes; detecting ~20–25% of cases) and Next-Generation Sequencing (NGS) nuclear gene panel / Whole Exome Sequencing (WES) for nuclear-encoded mitochondrial genes (e.g., SURF1, NDUFV1, SDHA, PDHA1; accounting for ~75–80% of cases).
4. Management Protocol:
   • Acute Resuscitation:
     • Intravenous hydration with 10% Dextrose in 0.45% Saline at 1.5 times maintenance; strictly avoid lactate-containing fluids (Ringer lactate contraindicated).
     • Avoid high-glucose boluses if pyruvate dehydrogenase (PDH) deficiency is suspected (where a ketogenic diet is indicated).
     • Correction of severe acidosis with intravenous sodium bicarbonate if pH < 7.15.
     • Avoid mitochondrial toxins (e.g., sodium valproate, aminoglycosides, linezolid, propofol, chloramphenicol).
   • Empiric Long-term Mitochondrial Cocktail:
     • Thiamine (Vitamin B1): 100–300 mg/day orally or IV (critical for pyruvate dehydrogenase and SLC19A3 defects).
     • Biotin: 5–10 mg/kg/day orally (to treat biotin-thiamine-responsive basal ganglia disease).
     • Coenzyme Q10 (Ubiquinone): 10–30 mg/kg/day divided twice daily.
     • L-Carnitine: 50–100 mg/kg/day orally divided in 3 doses.
     • Riboflavin (Vitamin B2): 100–200 mg/day orally.

1. Diagnosis and Subtype:
   • Metachromatic Leukodystrophy (MLD).
   • Late-infantile form (onset between 6 and 30 months of age).
2. Inheritance and Gene:
   • Mode of inheritance: Autosomal Recessive.
   • Causative gene: ARSA gene located on chromosome 22q13.33 (rarely, PSAP gene encoding Saposin B cofactor deficiency).
3. Deficient Enzyme and Accumulated Substrate:
   • Deficient enzyme: Arylsulfatase A (Cerebroside sulfatase).
   • Accumulated substrate: Galactosylceramide I3-sulfate (sulfatide / cerebroside sulfate).
4. Neuroimaging Features:
   • Symmetrical, confluent hyperintensity on T2/FLAIR in the periventricular and deep white matter (centrifugal progression from posterior periventricular regions).
   • Sparing of the subcortical arcuate (U-fibers) until late stages.
   • "Tigroid" or "leopard skin" pattern characterized by radiating stripes of preserved myelin along perivenular spaces within areas of confluent dysmyelination.
5. Electrophysiological Paradox:
   • MLD causes simultaneous central and peripheral demyelination (leukodystrophy plus peripheral demyelinating polyneuropathy).
   • Sulfatides accumulate within Schwann cells, causing severe motor-sensory demyelinating neuropathy with markedly reduced nerve conduction velocities (NCVs < 20 m/s). This peripheral deafferentation abolishes the deep tendon reflex arc, while corticospinal tract demyelination maintains pyramidal signs (spasticity, sustained extensor plantar responses).
6. Therapeutic Modalities:
   • Hematopoietic Stem Cell Transplantation (HSCT): Effective primarily in asymptomatic late-infantile siblings or early juvenile forms before major neurocognitive decline.
   • Ex vivo Autologous Hematopoietic Stem Cell Gene Therapy: Atidarsagene autotemcel (autologous CD34+ cells transduced with lentiviral vector encoding human ARSA cDNA), approved for presymptomatic late-infantile or early-symptomatic juvenile patients.

1. PECARN Risk Stratification ($\ge$ 2 years):
   • Risk category: Intermediate risk for ciTBI (~0.9% risk).
   • Identified PECARN risk factors in this patient:
     • History of loss of consciousness ($>5$ seconds).
     • History of vomiting ($\ge 2$ episodes).
     • Parietal scalp hematoma.
2. High-Risk Indicators Mandating Immediate Non-Contrast Head CT:
   • Glasgow Coma Scale (GCS) score $< 15$ at 2 hours post-injury.
   • Signs of basilar skull fracture (hemotympanum, "raccoon eyes" / periorbital ecchymosis, Battle sign / mastoid ecchymosis, CSF rhinorrhea / otorrhea).
   • Signs of depressed or open skull fracture.
   • History of altered mental status (e.g., lethargy, severe agitation, slow response, repetitive questioning).
3. Management Strategy for this Patient:
   • Decision between Observation vs. Immediate Head CT guided by shared decision-making with parents, physician experience, and clinical evolution:
     • Protocolized ED Observation: Observe the child for 4 to 6 hours from the time of injury without immediate CT. If the child remains GCS 15, vomiting ceases, and headache/irritability resolves, CT scan can be avoided and patient discharged.
     • Head CT Imaging: Proceed to non-contrast head CT if symptoms worsen during observation (worsening headache, persistent/recurrent vomiting $\ge 3$ times, progressive lethargy, or decline in GCS).
4. Indications for Urgent Neurosurgical Consultation:
   • Depressed skull fracture (especially if depressed $> 5$ mm or deeper than the inner table, or open/compound).
   • Extradural hematoma (EDH) or subdural hematoma (SDH) with mass effect, midline shift $> 5$ mm, or thickness $> 10$ mm.
   • Intracranial hemorrhage associated with persistent GCS decline $\ge 2$ points or development of focal neurological signs.
   • Refractory intracranial hypertension or cerebral herniation syndromes (unilateral dilated non-reactive pupil, Cushing triad: bradycardia, hypertension, irregular respirations).

1. Angiographic Findings and Diagnosis:
   • Angiographic Findings:
     • Severe bilateral (or unilateral) stenosis or occlusion of the terminal/supraclinoid segments of the internal carotid arteries (ICA) and proximal segments of the anterior (ACA) and middle cerebral arteries (MCA).
     • Proliferation of an abnormal network of fine, fragile collateral base-of-brain capillary vessels creating the pathognomonic "puff of smoke" (moyamoya) appearance.
   • Diagnosis: Moyamoya disease (or Moyamoya syndrome if secondary).
2. Distinction and Associated Conditions:
   • Moyamoya Disease: Idiopathic, non-atherosclerotic, bilateral vasculopathy in the absence of known predisposing systemic disorders (strongly associated with RNF213 gene variant p.R4810K in East Asians).
   • Moyamoya Syndrome: Moyamoya vasculopathy occurring secondary to recognized systemic conditions:
     • Sickle cell anemia / Hemoglobinopathies.
     • Down syndrome (Trisomy 21).
     • Neurofibromatosis type 1 (NF1).
     • Prior cranial irradiation.
3. Pathophysiology of Hyperventilation-Induced Ischemia:
   • Hyperventilation (during crying, blowing balloons, or vigorous exertion) induces acute respiratory alkalosis and profound hypocapnia ($\text{pCO}_2 < 30\text{ mmHg}$).
   • Hypocapnia triggers potent vasoconstriction of normal intracranial cerebral arterioles.
   • Because collateral vessels supplying ischemic territories are already maximally dilated (exhausted cerebral autoregulation), the relative constriction in surrounding vascular beds and steal phenomenon causes severe, critical hypoperfusion to the vulnerable cortex, provoking transient ischemic attack (TIA) or stroke.
4. Management Protocol:
   • Acute / Medical Therapy:
     • Low-dose Aspirin: 3–5 mg/kg/day orally once daily (inhibits platelet aggregation and collateral microthrombosis).
     • Avoid dehydration, arterial hypotension, hyperthermia, and hyperventilation; maintain liberal intravenous or oral hydration.
   • Surgical Revascularization (Definitive Management):
     • Direct Revascularization: Superficial Temporal Artery to Middle Cerebral Artery (STA-MCA) bypass (preferred in older children/adolescents with vessels $> 1\text{ mm}$).
     • Indirect Revascularization: Preferred in young children:
       • Encephaloduroarteriosynangiosis (EDAS).
       • Encephalomyosynangiosis (EMS).
       • Pial synangiosis or multiple burr holes.

1. Anatomical and Embryological Diagnosis:
   • Open myelomeningocele (neural tube defect resulting from failure of closure of the posterior neural tube / primary neurulation at the caudal neuropore by embryonic day 28).
2. Recurrence Risks in Subsequent Pregnancies:
   • Recurrence risk after 1 affected child: 3% to 4%.
   • Recurrence risk after 2 affected children: 10%.
3. Periconceptional Folic Acid Protocol:
   • Primary Prevention (Low Risk):
     • Dose: 0.4 mg (400 mcg) per day orally.
     • Duration: Commenced at least 1 month prior to conception and continued through the end of the first trimester (12 weeks of gestation).
   • Secondary Prevention (High Risk / Prior Affected NTD):
     • Dose: 4.0 mg (4000 mcg) per day orally.
     • Duration: Commenced at least 1 to 3 months prior to planned conception and continued through the first 12 weeks of gestation.
4. Immediate Pre-operative Bedside Care:
   • Place infant in a strict prone or lateral decubitus position to avoid direct pressure on the lesion.
   • Cover the open neural placode with sterile non-adherent gauze soaked in warm normal saline ($0.9\%\text{ NaCl}$); overwrap with sterile clear plastic wrap (e.g., plastic cling film) to prevent desiccation, evaporative heat loss, and bacterial contamination.
   • Strict avoidance of latex-containing materials (universal latex-free precautions to prevent severe latex sensitization).
   • Maintain normothermia; radiant warmer preferred over incubators to facilitate visual monitoring.
   • Initiate broad-spectrum intravenous antibiotic coverage (e.g., Ampicillin 100 mg/kg/day + Gentamicin 5 mg/kg/day or Cefotaxime 100 mg/kg/day) to prevent ventriculitis/meningitis.
   • Plan surgical closure within 24 to 48 hours of life.
5. Associated Malformation and Neuro-Urological Monitoring:
   • Associated Hindbrain Malformation: Chiari Type II malformation (downward herniation of cerebellar vermis, brainstem, and fourth ventricle through the foramen magnum).
   • Neuro-Urological Monitoring Modalities:
     • Serial baseline renal and bladder ultrasound (evaluating hydronephrosis, hydroureter, and post-void residual urine volume).
     • Urodynamic studies (UDS) / Videourodynamics (to assess detrusor sphincter dyssynergia and bladder compliance).
     • Initiate Clean Intermittent Catheterization (CIC) to prevent upper urinary tract deterioration.

1. Neuroanatomical Localization of Signs:
   • Bilateral pinpoint reactive pupils: Pons (pontine tegmentum / sympathetic tract disruption).
   • Midposition, fixed pupils: Midbrain tectum / dorsal midbrain (pretectal lesion disrupting both sympathetic and parasympathetic fibers).
   • Unilateral dilated, non-reactive pupil: Ipsilateral oculomotor nerve (cranial nerve III) compression at the tentorial notch (uncal herniation).
   • Conjugate horizontal deviation toward hemispehere: Ipsilateral frontal eye field (Brodmann area 8) destructive cortical lesion.
   • Ocular bobbing: Bilateral pontine tegmental destruction / central pontine lesion.
2. Marcus Gunn Pupil Pathophysiology and Elicitation:
   • Pathophysiology: Unilateral or asymmetrical lesion of the afferent visual pathway (retina or optic nerve), resulting in reduced sensory input to the pretectal nuclei in the midbrain while the efferent oculomotor parasympathetic pathways remain intact.
   • Elicitation (Swinging Flashlight Test): Move a focal penlight rapidly from the unaffected eye to the affected eye. When light shines on the affected eye, both pupils paradoxically dilate rather than constrict, because the afferent stimulus is weaker than that received when illuminating the healthy eye.
3. Differentiation of Cortical vs. Pontine Lesions:
   • Cortical (Frontal Eye Field) Destructive Lesion:
     • Eyes deviate conjugate toward the side of the lesion ("look at the lesion").
     • Hemiparesis is on the contralateral side ("eyes look away from the hemiparesis").
     • Doll's eye reflex (oculocephalic maneuver) remains intact and overcomes the deviation.
   • Pontine (PPRF / Abducens Nucleus) Destructive Lesion:
     • Eyes deviate conjugate away from the side of the lesion ("look away from the lesion").
     • Hemiparesis is on the contralateral side ("eyes look toward the hemiparesis").
     • Doll's eye reflex is absent or impaired.
4. Pupillary Stages of Central Transtentorial Herniation:
   • Diencephalic Stage: Small (1–3 mm), reactive pupils bilaterally (sympathetic disruption).
   • Midbrain Stage: Midposition (4–5 mm), fixed, non-reactive, often irregular pupils (loss of sympathetic and parasympathetic tone).
   • Pontomedullary Stage: Fully dilated, fixed pupils (terminal brainstem failure / cerebral circulatory arrest).

1. Dermatologic Lesion:
   • Café-au-lait macule (CALM).
2. NF1 Diagnostic Criteria for Café-au-Lait Macules:
   • Six or more café-au-lait macules with greatest diameter:
     • $> 5\text{ mm}$ in prepubertal individuals.
     • $> 15\text{ mm}$ in postpubertal individuals.
3. X-Linked Dominant Neurocutaneous Syndrome and Stages:
   • Syndrome: Incontinentia Pigmenti (Bloch-Sulzberger syndrome; IKBKG/NEMO gene mutation).
   • Four Dermatologic Stages:
     • Stage 1 (Vesicular/Bullous): Linear inflammatory vesicles and pustules (birth to 4 months).
     • Stage 2 (Verrucous): Hyperkeratotic, warty plaques along Blaschko's lines (months 2 to 6).
     • Stage 3 (Hyperpigmented): Swirled or reticulated hyperpigmentation ("marble cake" appearance) along Blaschko's lines (infancy through adolescence).
     • Stage 4 (Atrophic/Hypopigmented): Pale, hairless, anhidrotic linear streaks or patches (adulthood).
4. Mathematical Calculation of Recurrence Risk:
   $$ > \begin{aligned} > \text{Probability of Transmission} &= \text{Germline Mosaicism Fraction} \times \text{Allele Segregation Probability} \\ > &= 0.30 \times 0.50 \\ > &= \mathbf{0.15 \text{ or } 15\%} > \end{aligned} > $$

1. Diagnosis and Genetics:
   • Diagnosis: Neurofibromatosis Type 1 (NF1 / von Recklinghausen disease).
   • Mode of Inheritance: Autosomal dominant (with 50% representing de novo mutations).
   • Causative Gene: NF1 gene.
   • Chromosomal Locus: Chromosome 17q11.2.
   • Encoded Protein: Neurofibromin (a GTPase-activating protein that negative-regulates the RAS/MAPK pathway).
2. 2021 Revised International NF1 Diagnostic Criteria (requires $\ge 2$ of the following in an individual without an affected parent):
   • Six or more café-au-lait macules ($>5\text{ mm}$ in prepubertal, $>15\text{ mm}$ in postpubertal).
   • Freckling in the axillary or inguinal regions (Crowe sign).
   • Two or more neurofibromas of any type or one plexiform neurofibroma.
   • Optic pathway glioma.
   • Two or more iris Lisch nodules (identified by slit lamp) OR two or more choroidal abnormalities (identified by optical coherence tomography / near-infrared imaging).
   • A distinctive osseous lesion (sphenoid wing dysplasia, anterolateral bowing of tibia, or pseudoarthrosis of long bone).
   • A heterozygous pathogenic NF1 variant with variant allele fraction of 50% in normal tissue.
   • A parent meeting the above criteria for NF1.
3. Intracranial and Vascular Complications:
   • Focal areas of signal intensity (FASI / T2-hyperintense myelin vacuolation / "unidentified bright objects" [UBOs]).
   • Optic pathway gliomas (pilocytic astrocytoma) and non-optic low-grade astrocytomas.
   • Moyamoya arteriopathy / cerebral vasculopathy with stenosis of internal carotid branches.
4. Targeted Molecular Therapy:
   • Drug: Selumetinib.
   • Mechanism: Selective oral Mitogen-Activated Protein Kinase Kinase 1 and 2 (MEK 1/2) inhibitor.
   • Dose: $25\text{ mg/m}^2/\text{dose}$ orally twice daily on an empty stomach (1 hour before or 2 hours after meals), continuously until disease progression or unacceptable toxicity.

1. Diagnosis and Inheritance:
   • Diagnosis: Neuronal Ceroid Lipofuscinosis (NCL / Batten disease; infantile [CLN1] or late-infantile [CLN2] form).
   • Inheritance: Autosomal recessive.
2. Ultrastructural and Histological Hallmarks:
   • Electron Microscopy Ultrastructure:
     • Granular osmiophilic deposits (GRODs) in CLN1.
     • Curvilinear bodies (CVBs) in CLN2.
     • Fingerprint profiles (FPPs) in CLN3.
   • Staining Property: Autofluorescent lipopigments showing positive staining with Luxol fast blue, Periodic acid–Schiff (PAS), and Sudan black B; persistent yellow-orange autofluorescence under ultraviolet light microscopy.
3. Enzyme Deficiencies and Genetic Subtypes:
   • Infantile NCL (CLN1): Palmitoyl-protein thioesterase 1 (PPT1) deficiency; PPT1 gene on chromosome 1p34.
   • Late-Infantile NCL (CLN2): Tripeptidyl peptidase 1 (TPP1) deficiency; TPP1 gene on chromosome 11p15.
4. Disease-Modifying Therapy for CLN2:
   • Drug: Cerliponase alfa (recombinant human tripeptidyl peptidase 1 [rhTPP1]).
   • Route: Intraventricular infusion via an surgically implanted reservoir/catheter system (Ommaya reservoir).
   • Dose & Schedule: $300\text{ mg}$ administered every other week (once every 14 days) over 4 to 4.5 hours, followed by intraventricular electrolyte flush.

1. Diagnosis and EEG Hallmark:
   • Diagnosis: Nonketotic Hyperglycinemia (NKH / Neonatal Glycine Encephalopathy).
   • Classic EEG Pattern: Burst-suppression pattern (high-voltage paroxysmal bursts of spikes and polyspikes alternating with periods of isoelectric suppression).
2. Calculation of CSF-to-Plasma Glycine Ratio:
   $$ > \begin{aligned} > \text{CSF:Plasma Glycine Ratio} &= \frac{\text{CSF Glycine Concentration } (\mu\text{mol/L})}{\text{Plasma Glycine Concentration } (\mu\text{mol/L})} \\ > &= \frac{120\,\mu\text{mol/L}}{800\,\mu\text{mol/L}} \\ > &= \mathbf{0.15} > \end{aligned} > $$
   • Interpretation: Diagnostic. A CSF:plasma glycine ratio $> 0.08$ (normal reference $< 0.02$) is diagnostic of nonketotic hyperglycinemia.
3. Defective Enzyme Complex and Genes:
   • Enzyme Complex: Glycine Cleavage System (GCS / Glycine Decarboxylase multienzyme complex), comprising four components: P-protein, T-protein, H-protein, and L-protein.
   • Genes:
     • GLDC (encodes P-protein / pyridoxal phosphate-dependent decarboxylase, ~80% of cases).
     • AMT (encodes T-protein / tetrahydrofolate-dependent aminomethyltransferase, ~15% of cases).
     • GCSH (encodes H-protein / lipoic acid-containing shuttle protein, $<1\%$ of cases).
4. Pharmacotherapeutic Protocol:
   • NMDA Receptor Antagonism:
     • Dextromethorphan: $5\text{ to }15\text{ mg/kg/day}$ orally divided every 6 to 8 hours (blocks overactivation of NMDA receptors by glycine).
     • Alternate/adjunctive: Ketamine ($1\text{ to }2\text{ mg/kg/day}$).
   • Glycine Scavenging:
     • Sodium Benzoate: $250\text{ to }750\text{ mg/kg/day}$ orally or intravenously divided every 6 hours (conjugates with glycine via glycine N-acyltransferase to form hippuric acid, excreted in urine; target plasma glycine level: $200\text{ to }300\,\mu\text{mol/L}$).

• Glycine acts as an inhibitory neurotransmitter in the spinal cord and brainstem (via strychnine-sensitive glycine receptors), causing profound neonatal hypotonia, hypoventilation, apnea, and hiccups.
• Concurrently, glycine acts as an obligate co-agonist at the NMDA receptor in the cerebral cortex and hippocampus, leading to excitotoxicity, intractable myoclonic seizures, and progressive brain atrophy.
• Ketosis and metabolic acidosis are absent because glycine cleavage defect does not directly impair gluconeogenesis, fatty acid oxidation, or the Krebs cycle, differentiating NKH from organic acidemias (e.g., propionic acidemia, methylmalonic acidemia) which can cause secondary "ketotic hyperglycinemia."

1. Diagnosis:
   • Occult spinal dysraphism / Closed neural tube defect (specifically Lipomyelomeningocele / Lumbosacral lipoma).
2. Cutaneous Midline Markers (Any 4):
   • Hypertrichosis (faun tail or localized tuft of hair).
   • Dermal sinus tract or deep midline dimple situated $>2.5\text{ cm}$ above the anal verge or within the gluteal cleft.
   • Capillary malformation (midline port-wine stain / hemangioma).
   • Atypical skin appendages or pseudotails / true human tails.
   • Midline hypopigmented or hyperpigmented macule.
3. Recurrence Risk:
   • One affected sibling: $3\text{--}4\%$ risk of recurrence in subsequent pregnancies.
   • Two affected siblings: Approximately $10\%$ risk of recurrence.
4. Chemoprophylaxis Regimen:
   • Drug: High-dose oral folic acid.
   • Dose: $4\text{ mg/day}$ ($4000\ \mu\text{g/day}$) orally (compared to $0.4\text{ mg/day}$ or $400\ \mu\text{g/day}$ for standard low-risk pregnancies).
   • Timing and Duration: Initiated at least $1\text{ to }3\text{ months}$ prior to conception and continued through at least the end of the first trimester ($12\text{ weeks}$ of gestation).

Uncorrected lesions frequently lead to tethered cord syndrome as the vertebral column outgrows the spinal cord, presenting later in childhood with progressive asymmetric lower limb weakness, foot deformities (cavovarus), gait disturbances, scoliosis, and neurogenic bladder/bowel dysfunction. Early spinal ultrasound ($<3\text{--}4\text{ months}$ before posterior element ossification) or definitive spinal MRI ($>3\text{--}4\text{ months}$) is mandatory to plan elective detethering surgery before irreversible neurological deficits occur.

1. Diagnosis:
   • Pantothenate kinase-associated neurodegeneration (PKAN; formerly known as Hallervorden-Spatz disease), classified under Neurodegeneration with Brain Iron Accumulation (NBIA Type 1).
2. Genetics:
   • Mutated Gene: PANK2 gene (located on chromosome 20p13, encoding the mitochondrial enzyme pantothenate kinase 2).
   • Mode of Inheritance: Autosomal recessive.
3. Neuroimaging Finding & Pathophysiology:
   • MRI Finding: "Eye-of-the-tiger" sign on T2-weighted or susceptibility-weighted (SWI) MRI.
   • Pathological Basis: A central zone of high T2 signal intensity (hyperintensity) representing tissue necrosis, vacuolization, and gliosis within the anterior globus pallidus, surrounded by a peripheral rim of marked low T2 signal intensity (hypointensity) caused by excessive iron (ferritin/hemosiderin) deposition.
4. Therapeutic Agents:
   • Symptomatic Antidystonic Therapy (Any 2):
     • Oral Baclofen: $0.3\text{--}2.0\text{ mg/kg/day}$ divided every 8 hours (or intrathecal baclofen pump for severe generalized dystonia).
     • Oral Trihexyphenidyl: $0.1\text{--}0.5\text{ mg/kg/day}$ divided every 8 hours, titrated gradually.
     • Oral Clonazepam: $0.01\text{--}0.05\text{ mg/kg/day}$ divided every 8 to 12 hours.
   • Targeted Iron Chelator:
     • Deferiprone ($15\text{--}30\text{ mg/kg/dose}$ orally twice daily; crosses blood-brain barrier).

1. Diagnosis:
   • Pediatric Migraine without aura (ICHD-3 code 1.1).
2. Standardized Functional Tool:
   • PedMIDAS (Pediatric Migraine Disability Assessment Score).
3. ICHD-3 Diagnostic Criteria in Children:
   • A: At least 5 attacks fulfilling criteria B through D.
   • B (Duration): Headache attacks lasting $2\text{ to }72\text{ hours}$ (untreated or unsuccessfully treated); note that in children $<18\text{ years}$, attacks may last $1\text{ to }72\text{ hours}$ (or $2\text{ to }72\text{ hours}$ strictly per ICHD-3 text, with untreated durations down to 30 minutes to 2 hours acknowledged in younger children).
   • C (Characteristics): At least two of the following four features:
     • Bilateral (frontotemporal) or unilateral location (bilateral is more common in younger children).
     • Pulsating or throbbing quality.
     • Moderate to severe pain intensity.
     • Aggravation by or causing avoidance of routine physical activity (e.g., walking, climbing stairs).
   • D (Accompanying Features): During headache, at least one of:
     • Nausea and/or vomiting.
     • Photophobia AND phonophobia (in children, this can be inferred from behavior).
   • E: Not better accounted for by another ICHD-3 diagnosis.
4. Management:
   • Acute Abortive Therapy (Either of following):
     • Oral Ibuprofen: $10\text{ mg/kg/dose}$ (maximum $400\text{--}600\text{ mg/dose}$) administered at earliest onset of headache.
     • Oral/Nasal Sumatriptan (for children $\ge 6\text{--}12\text{ years}$ refractory to NSAIDs): Nasal spray $5\text{--}20\text{ mg}$ single dose or oral $25\text{--}50\text{ mg}$ single dose.
   • Indications for Prophylaxis (Any 2):
     • Frequent attacks ($\ge 3\text{ to }4$ disabling headaches per month or $>1\text{ episode/week}$).
     • PedMIDAS score $>30$ or $>50$ (moderate-to-severe disability / frequent school absenteeism).
     • Acute abortive therapies are ineffective, poorly tolerated, or contraindicated.
     • Hemiplegic migraine, brainstem aura, or prolonged aura episodes.

1. Radiological Sign & Diagnosis:
   • Radiological Sign: Empty delta sign (triangle sign / delta sign) on axial post-contrast CT; characterized by a non-enhancing, low-attenuation central intraluminal thrombus bounded by triangular intensely enhancing dura/sinus collateral collateral channels in the posterior superior sagittal sinus.
   • Definitive Diagnosis: Cerebral Venous Sinus Thrombosis (CVST) involving the superior sagittal sinus.
2. Pediatric Risk Factors (Any 4):
   • Severe systemic dehydration / hypernatremic dehydration.
   • Systemic sepsis or contiguous head/neck infections (mastoiditis, sinusitis, otitis media).
   • Cyanotic congenital heart disease with secondary polycythemia.
   • Inherited thrombophilias (Factor V Leiden mutation, Prothrombin G20210A, Antithrombin III deficiency, Protein C or S deficiency).
   • Nephrotic syndrome (urinary loss of Antithrombin III) or diabetic ketoacidosis.
3. Pathophysiology Comparison:
   • CVST (Venous Stroke): Occlusion of cerebral venous drainage leads to increased retrograde venous and capillary hydrostatic pressure, breakdown of the blood-brain barrier causing vasogenic edema, followed by reduction in capillary perfusion causing secondary cytotoxic edema, venous petechiae, and high-pressure hemorrhagic transformation (venous infarction).
   • Arterial Ischemic Stroke: Occlusion of arterial inflow causes immediate delivery failure of glucose and oxygen, rapid failure of $Na^+/K^+\text{-ATPase}$ pumps, cellular swelling (cytotoxic edema predominant within minutes to hours), with hemorrhagic transformation occurring only secondarily during reperfusion into necrotic capillary beds.
4. Anticoagulation Protocol:
   • Initial Acute Agent: Low Molecular Weight Heparin (Enoxaparin).
   • Dose:
     • Children $\ge 2\text{ months to }18\text{ years}$: $1.0\text{ mg/kg/dose}$ subcutaneously every 12 hours.
     • (Infants $<2\text{ months}$: $1.5\text{ mg/kg/dose}$ subcutaneously every 12 hours).
   • Monitoring: Anti-Factor Xa activity level measured 4 hours after the 3rd or 4th subcutaneous dose; target therapeutic range is $0.5\text{ to }1.0\text{ units/mL}$.
   • Duration: $3\text{ months}$ for a provoked event secondary to a transient risk factor (e.g., dehydration/infection) with radiological resolution; extended to $6\text{ to }12\text{ months}$ if unprovoked or associated with persistent prothrombotic states.

1. Matching:
   • Scenario 1 $\rightarrow$ e (Provisional / transient tic disorder of childhood)
   • Scenario 2 $\rightarrow$ c (Tourette syndrome)
   • Scenario 3 $\rightarrow$ d (Spastic diplegic cerebral palsy)
   • Scenario 4 $\rightarrow$ b (McCune-Albright syndrome)
   • Scenario 5 $\rightarrow$ a (Tuberous sclerosis complex)
2. Differentiating Criteria (DSM-5):
   • Tourette Syndrome (Scenario 2): Both multiple motor tics AND at least one vocal tic must be present concurrently or at different times, with a total duration persisting for more than 1 year ($\ge 12\text{ months}$) since first tic onset, starting before age 18 years.
   • Provisional Tic Disorder (Scenario 1): Single or multiple motor and/or vocal tics present for less than 1 year ($<12\text{ months}$) consecutively since first tic onset, without having ever fulfilled criteria for Tourette syndrome.
3. Management of Tourette Syndrome:
   • First-line Behavioral Intervention: Comprehensive Behavioral Intervention for Tics (CBIT), incorporating Habit Reversal Training (HRT) and exposure with response prevention.
   • Pharmacotherapy Options:
     • Alpha-2 adrenergic agonists (first-line pharmacologic): Clonidine ($0.05\text{--}0.2\text{ mg/day}$) or Guanfacine ($0.5\text{--}3\text{ mg/day}$).
     • Atypical antipsychotics: Aripiprazole ($2\text{--}10\text{ mg/day}$) or Risperidone ($0.25\text{--}2\text{ mg/day}$).
4. Surveillance in Tuberous Sclerosis Complex (Scenario 5):
   • CNS Lesions (Subependymal Giant Cell Astrocytoma / SEGA): Brain MRI with contrast every $1\text{ to }3\text{ years}$ until age 25 years (or until maturity/stability), with immediate imaging if symptoms of raised intracranial pressure develop.
   • Renal Lesions (Angiomyolipomas / Cysts): Abdominal MRI (preferred) or renal ultrasonography every $1\text{ to }3\text{ years}$ throughout lifetime; annual blood pressure measurement and annual serum creatinine/eGFR.

1. MRI Brain Findings:
   • Extensive bilateral multifocal cystic encephalomalacia involving the cerebral cortex and subcortical white matter.
   • Confluent volume loss with compensatory ex vacuo dilatation of the lateral and third ventricles.
   • Marked thinning and atrophy of the corpus callosum.
   • Diffuse ulegyria (shrunken, mushroom-shaped gyri with deep sulcal preservation) and cerebellar volume reduction.
2. Definitive Diagnosis & Timing:
   • Diagnosis: Multicystic encephalomalacia secondary to severe perinatal Hypoxic-Ischemic Encephalopathy (HIE) / Perinatal Asphyxia.
   • Timing: Intrapartum / perinatal period (acute profound or prolonged partial hypoxic-ischemic insult in a term infant).
3. Pathophysiological Vulnerability Patterns:
   • Term Infants ($\ge 37$ weeks):
     • High metabolic rate and dense distribution of N-methyl-D-aspartate (NMDA) glutamate receptors in mature structures.
     • Profound acute insults preferentially damage the deep grey nuclei (putamen, thalamus, peri-rolandic cerebral cortex).
     • Prolonged partial asphyxia predominantly damages the parasagittal watershed/border-zone cortical regions.
   • Preterm Infants ($<34$ weeks):
     • Vulnerability is concentrated in the periventricular white matter (periventricular leukomalacia - PVL).
     • Immature pre-oligodendrocytes (O4/O1 positive) are exquisitely susceptible to free radical injury, excitotoxicity, and microvascular end-zone ischemia.
     • Propensity for germinal matrix hemorrhage-intraventricular hemorrhage (GMH-IVH) due to fragile subependymal capillary networks.
4. Management Protocol for Spasticity:
   • Multidisciplinary Neurorehabilitation:
     • Intensive physical therapy to prevent contractures, maintain joint range of motion, and facilitate functional motor patterns.
     • Occupational therapy with adaptive seating systems and ankle-foot orthoses (AFOs).
   • Pharmacotherapy for Spasticity:
     • Oral Baclofen (GABA-B agonist): Initiate at $0.3\text{ mg/kg/day}$ orally divided TID; titrate weekly by $0.3\text{ mg/kg/day}$ up to a maintenance dose of $1.0\text{--}1.5\text{ mg/kg/day}$ (maximum: $2.0\text{ mg/kg/day}$ or $40\text{ mg/day}$ in young children).
     • Diazepam (adjunct for severe painful spasms): $0.12\text{--}0.8\text{ mg/kg/day}$ orally divided TID/QID.
     • Focal Spasticity: Botulinum Toxin A injections ($3\text{--}6\text{ units/kg/muscle}$ of onabotulinumtoxinA) targeted to dynamic calf or hamstring contractures under ultrasound guidance.

1. Image Interpretation and Diagnoses:
   • Image A: Marked cystic enlargement of the posterior fossa communicating with the fourth ventricle, severe cerebellar vermian hypoplasia/agenesis with upward rotation of the vermian remnant, and an elevated tentorium/torcular herophili. $\rightarrow$ Dandy-Walker Malformation.
   • Image B: Herniation of peg-like cerebellar tonsils extending $>5\text{ mm}$ below the horizontal line connecting the basion and opisthion (foramen magnum). $\rightarrow$ Chiari I Malformation.
   • Image C: Low-lying torcular herophili with small posterior fossa, beaked tectal plate, caudal displacement of the vermis, fourth ventricle, and medulla into the cervical spinal canal ("Z-kinking" of the cervicomedullary junction), associated with lumbar myelomeningocele. $\rightarrow$ Chiari II Malformation.
2. Diagnostic Triad for Dandy-Walker Malformation:
   • Complete or partial agenesis/hypoplasia of the cerebellar vermis with counter-clockwise anterior-superior rotation.
   • Marked cystic dilatation of the fourth ventricle filling the entire posterior cranial fossa.
   • Upward displacement of the tentorium cerebelli, torcular herophili, and transverse sinuses (torcular-lambdoid inversion).
   • Differential feature: Mega cisterna magna possesses an intact vermis and normal fourth ventricle; retrocerebellar arachnoid cyst displaces an intact vermis and non-dilated fourth ventricle anteriorly without communication.
3. Management of Chiari I Malformation:
   • Indications for Surgery: Symptomatic tussive/Valsalva-induced suboccipital headaches, progressive cervical syringomyelia, lower cranial nerve palsies (dysphagia, stridor), sleep apnea, or progressive myelopathy.
   • Surgical Procedure: Posterior fossa decompression (craniectomy of the suboccipital bone and C1 posterior arch laminectomy) with or without duraplasty and tonsillar shrinkage/resection.
4. Systematic 5-Step Evaluation Checklist:
   • Step 1: Posterior Fossa Volume & Infratentorial Compartment Size: Assess for enlargement (Dandy-Walker) versus abnormally diminutive volume (Chiari II).
   • Step 2: Cerebellar Vermis Morphology: Examine vermian presence, segmentation (primary and secondary fissures), rotation, and volume.
   • Step 3: Fourth Ventricle Configuration: Check whether the fourth ventricle is dilated and communicating with a cyst, effaced, or downwardly displaced.
   • Step 4: Foramen Magnum & Craniocervical Junction: Measure metric tonsillar descent below the basion-opisthion line ($>5\text{ mm}$ diagnostic of tonsillar ectopia) and assess cervicomedullary kinking.
   • Step 5: Associated Supratentorial & Spinal Cord Anomalies: Screen for hydrocephalus, corpus callosum dysgenesis, tectal beaking, syringomyelia/hydromyelia, and spinal dysraphism.

1. MRI Interpretation and Differentials:
   • Findings: Well-circumscribed, solid-cystic midline posterior fossa mass arising from the cerebellar vermis and roof of the fourth ventricle. Displays T1 hypointensity, T2/FLAIR heterogeneous hyperintensity, marked restricted diffusion on DWI (high cellularity with low ADC values), and robust heterogeneous contrast enhancement. Causes compression of the fourth ventricle resulting in upstream tri-ventricular obstructive hydrocephalus.
   • Diagnosis: Medulloblastoma (WHO Grade 4 embryonal neoplasm).
   • Differential Diagnoses:
     • Pilocytic astrocytoma (cystic with enhancing mural nodule, no diffusion restriction).
     • Ependymoma (arises from the floor of the fourth ventricle, plastically extends through the foramina of Luschka/Magendie, variable calcification).
     • Atypical Teratoid/Rhabdoid Tumor (ATRT) (younger age $<3\text{ years}$, INI1/SMARCB1 loss).
2. WHO CNS5 Molecular Subgroups & Prognosis:
   • WNT-activated: Excellent prognosis ($>95\%$ 5-year overall survival; classic histology, nuclear $\beta$-catenin positivity, monosomy 6).
   • SHH-activated (TP53-wildtype): Intermediate to good prognosis; desmoplastic/nodular histology common.
   • SHH-activated (TP53-mutant): Dismal/very poor prognosis; frequent anaplastic histology and high recurrence.
   • Non-WNT/Non-SHH (Group 3): Poor prognosis (frequent MYC amplification, early leptomeningeal metastasis, $<50\%$ 5-year survival).
   • Non-WNT/Non-SHH (Group 4): Intermediate prognosis (most common subgroup, isochromosome 17q, moderate metastatic risk).
3. Clinical Risk Stratification (for children $\ge 3$ years):
   • Standard-Risk (Average-Risk):
     • Age $\ge 3$ years.
     • Total or near-total surgical resection (residual tumor area $<1.5\text{ cm}^2$ on postoperative MRI within 48–72 hours).
     • Stage M0 (no neuraxis dissemination on craniospinal MRI and lumbar CSF cytology).
   • High-Risk:
     • Age $<3$ years at diagnosis.
     • Subtotal resection with residual tumor area $\ge 1.5\text{ cm}^2$.
     • Metastatic dissemination (M1: microscopic CSF tumor cells; M2: intracranial subarachnoid seeding; M3: spinal subarachnoid seeding; M4: extraneural spread).
     • Molecular high-risk features (e.g., MYC amplification, somatic/germline TP53 mutation).
4. Multimodal Management Protocol:
   • Surgical Resection: Maximal safe surgical resection aiming for complete gross excision while preserving brainstem and cerebellar function. Immediate management of hydrocephalus via external ventricular drain (EVD) or endoscopic third ventriculostomy (ETV) if indicated.
   • Craniospinal Irradiation (CSI) (in children $>3$ years):
     • Standard Risk: Low-dose CSI of $23.4\text{ Gy}$ in 13 fractions, followed by a conformal boost to the primary tumor bed to a total cumulative dose of $54.0\text{--}55.8\text{ Gy}$.
     • High Risk: Conventional-dose CSI of $36.0\text{ Gy}$, with tumor bed boost up to $54.0\text{--}55.8\text{ Gy}$, and focal boosts of $45.0\text{--}50.0\text{ Gy}$ to metastatic spinal deposits.
   • Adjuvant Chemotherapy (Packer Protocol):
     • Concurrent craniospinal radiotherapy with weekly intravenous Vincristine ($1.5\text{ mg/m}^2/\text{week}$, max single dose $2.0\text{ mg}$).
     • Maintenance cyclic chemotherapy (typically 6–8 cycles) consisting of:
       • Cisplatin: $75\text{ mg/m}^2/\text{cycle}$ IV.
       • Lomustine (CCNU): $75\text{ mg/m}^2/\text{cycle}$ orally on day 1.
       • Vincristine: $1.5\text{ mg/m}^2/\text{dose}$ IV on days 1, 8, and 15 of every 6-week cycle.
       • Alternative regimen: Cyclophosphamide replacing Lomustine in high-risk regimens.

1. Diagnosis & Diagnostic Criteria:
   • Diagnosis: Secondary Pseudotumor Cerebri Syndrome (Benign/Idiopathic Intracranial Hypertension) induced by acute hypervitaminosis A toxicity.
   • Modified Dandy Criteria (Friedman 2013 Pediatric Modification):
     • Signs and symptoms of increased intracranial pressure (headache, vomiting, irritability, bulging fontanelle, abducens palsy, papilledema).
     • Absence of focal neurological deficits (except unilateral or bilateral abducens nerve palsy).
     • Normal neuroimaging excluding hydrocephalus, space-occupying lesion, meningeal enhancement, or venous sinus thrombosis.
     • Elevated CSF opening pressure measured in lateral decubitus position.
     • Normal CSF cytological, chemical, and microbiological composition.
     • No identifiable alternative systemic cause.
2. Expected CSF Findings:
   • Opening Pressure: Markedly elevated ($>28\text{ cm H}_2\text{O}$ or $>280\text{ mm H}_2\text{O}$ in a sedated infant; $>25\text{ cm H}_2\text{O}$ in a calm/non-sedated infant; normal infant threshold is $<18\text{--}20\text{ cm H}_2\text{O}$).
   • Cell Count / Cytology: Normal ($<5\text{ leukocytes}/\mu\text{L}$, no pleocytosis).
   • Biochemistry:
     • Protein: Normal ($15\text{--}45\text{ mg/dL}$).
     • Glucose: Normal ($45\text{--}80\text{ mg/dL}$ or CSF:plasma ratio $>0.60$).
3. Mathematical Exceedance & Pathophysiology:
   $$ > \begin{aligned} > \text{Recommended Prophylactic Dose (6--11 months)} &= 100,000\text{ IU orally} \\ > \text{Dose Administered} &= 500,000\text{ IU orally} \\ > \text{Fold Exceedance} &= \frac{500,000\text{ IU}}{100,000\text{ IU}} = \mathbf{5\text{-fold excess}} > \end{aligned} > $$
   • Pathophysiology: High-dose retinol and its active metabolite (retinoic acid) overload plasma retinol-binding protein (RBP), yielding unbound circulating retinoic acid. This lipophilic compound increases microvascular permeability of the choroid plexus and upregulates arachnoid villi endothelial tight junctions, causing a mismatch between CSF production and bulk absorption across arachnoid granulations.
4. Therapeutic Protocol:
   • Immediate Cessation: Permanently discontinue all exogenous vitamin A and retinoid formulations.
   • Therapeutic Lumbar Puncture: Perform controlled drainage of CSF during diagnostic LP to normalize opening pressure to $<15\text{--}18\text{ cm H}_2\text{O}$, providing immediate symptomatic relief.
   • First-Line Pharmacotherapy:
     • Oral Acetazolamide (Carbonic anhydrase inhibitor): Initiate at $15\text{--}25\text{ mg/kg/day}$ orally divided TID; titrate upward based on tolerability and fontanelle tension to a maximum of $100\text{ mg/kg/day}$ (max $2\text{ g/day}$).
   • Second-Line / Adjunctive Agent:
     • Oral Furosemide: $1\text{ mg/kg/day}$ once daily or divided BID if acetazolamide is partially effective or poorly tolerated.
   • Monitoring Parameters:
     • Serum electrolytes and venous blood gas every 1–2 weeks (monitor for hypokalemia, hyperchloremic non-anion gap metabolic acidosis).
     • Serial ophthalmic evaluations (optic disc appearance and visual acuity/fixation) and weekly fontanelle tension checks.

1. Radiological Findings and Cranial Shape:
   • CT demonstrates premature osseous closure and sclerosis of the sagittal suture with bony bridging and loss of the radiolucent suture line.
   • Compensatory anteroposterior cranial expansion produces a scaphocephalic (dolichocephalic) skull with biparietal narrowing, compensatory frontal bossing, and prominent occipital bathrocephaly.
2. Diagnosis & Incidence:
   • Isolated (Non-syndromic) Sagittal Craniosynostosis (Scaphocephaly).
   • It is the most common form of single-suture craniosynostosis, accounting for approximately 50% to 60% of all non-syndromic synostosis cases (prevalence: 1 in 2,000 to 1 in 5,000 live births; male-to-female ratio: 3:1 to 4:1).
3. Mathematical Derivation:
   $$ > \begin{aligned} > \text{Cranial (Cephalic) Index (CI)} &= \frac{\text{Maximum Cranial Width (Biparietal Diameter)}}{\text{Maximum Cranial Length (Occipitofrontal Diameter)}} \times 100 \\ > &= \frac{84\text{ mm}}{130\text{ mm}} \times 100 \\ > &= \mathbf{64.6\%} \quad (\text{Reference Range: } 75.0\% - 85.0\%) > \end{aligned} > $$
   • A Cranial Index of $<70\%$ (or $<75\%$ depending on population standards) defines scaphocephaly/dolichocephaly.
4. Surgical Management & Timing:
   • Endoscopic Strip Craniectomy with Postoperative Helmet Molding Therapy:
     • Minimally invasive excision of the fused sagittal suture (3–4 cm wide strip).
     • Optimal window: 2 to 4 months of age (generally $<6$ months) while cranial bone remains highly malleable and brain growth rapidly drives re-expansion. Requires dynamic cranial orthosis (helmet) for 6–9 months post-procedure.
   • Open Calvarial Vault Remodeling (e.g., Modified Pi-procedure, Total Calvarial Reconstruction, or Biparietal Barrel-Stave Osteotomies):
     • Performed for late presentations (6 to 12 months of age), or if helmet therapy is not feasible.

1. EEG Abnormalities:
   • High-voltage (frequently $>150\ \mu\text{V}$), blunt, broad, diphasic or triphasic sharp-and-slow-wave complexes (centrotemporal spikes) with prominent following slow waves.
   • Localized to the centrotemporal electrodes (C3/C4, T3/T4) with horizontal dipole orientation (negativity in centrotemporal areas and positivity in the frontal regions).
   • Normal background rhythm; discharges increase in frequency during non-REM sleep.
2. Formal ILAE Diagnosis:
   • Self-Limiting Epilepsy with Centrotemporal Spikes (SeLECTS) (formerly known as Benign Childhood Epilepsy with Centrotemporal Spikes [BECTS] or Benign Rolandic Epilepsy).
3. Neuroanatomical Localization and Pathophysiology:
   • Localization: Lower part of the motor and sensory Rolandic cortex (pre- and post-central gyri around the central sulcus) controlling the face, lips, tongue, and pharynx.
   • Speech Inability (Anarthria/Speech Arrest): Caused by transient motor dysfunction and tonic/clonic spasm of the tongue, lips, and laryngeal muscles, rather than a cortical aphasia (the child maintains normal auditory comprehension and intact consciousness during the focal phase).
4. Management & Pharmacotherapy:
   • Indications for Pharmacotherapy: Frequent nocturnal seizures disruptive to sleep/family, daytime seizures, prolonged focal status epilepticus, or significant behavioral/neurocognitive dysfunction. (Because 10–25% experience only a single seizure and spontaneous remission occurs around puberty, treatment is not mandatory after a single event).
   • First-Line Antiseizure Medications:
     • Levetiracetam: $20\text{--}40\text{ mg/kg/day}$ divided PO twice daily (titrated up to $60\text{ mg/kg/day}$).
     • Sulthiame: $5\text{--}10\text{ mg/kg/day}$ divided PO twice daily (where available).
   • Medications Requiring Caution:
     • Carbamazepine / Oxcarbazepine: Although effective for focal seizures, they can paradoxically aggravate seizures or induce Developmental and Epileptic Encephalopathy with Spike-and-Wave Activation in Sleep (D-EE-SWAS / ESES) in susceptible patients.

1. Diagnosis and Refutation of ASD:
   • Primary Diagnosis: Severe-to-profound Congenital / Prelingual Bilateral Sensorineural Hearing Loss (SNHL).
   • Refutation of ASD:
     • Intact joint attention and non-verbal communicative intent (spontaneous proto-declarative pointing to direct adult attention to objects of interest).
     • Preserved socio-emotional reciprocity (sustained reciprocal eye contact, shared enjoyment, interactive games like peek-a-boo, and bringing objects to show caregivers).
2. Audiological Testing Battery:
   • Brainstem Evoked Response Audiometry (BERA) / Auditory Brainstem Response (ABR): Click-evoked and frequency-specific tone-burst ABR to objectively determine electrophysiological hearing thresholds.
   • Otoacoustic Emissions (OAE) (Distortion Product [DPOAE] or Transient Evoked [TEOAE]): Evaluates outer hair cell function of the cochlea (absent in sensory cochlear hearing loss; preserved in auditory neuropathy spectrum disorder [ANSD]).
   • Auditory Steady-State Response (ASSR): Provides frequency-specific threshold estimations across 500 Hz to 4,000 Hz.
   • Visual Reinforcement Audiometry (VRA): Age-appropriate conditioned behavioral testing (6 months to 2.5 years) performed in a sound-treated room.
   • Tympanometry with Acoustic Reflexes: Assesses middle ear compliance to rule out concurrent otitis media with effusion.
3. Etiological Workup:
   • Genetic Mutation: Pathogenic variants in the GJB2 gene on chromosome 13q12 (encoding the Gap Junction protein Connexin 26), accounting for up to 50% of autosomal recessive non-syndromic SNHL.
   • Cardiac Investigation: 12-lead Electrocardiogram (ECG) to measure the corrected QT interval ($\text{QTc}$) to rule out Jervell and Lange-Nielsen Syndrome (congenital bilateral profound SNHL + prolonged QTc leading to torsades de pointes and sudden cardiac death).
4. Rehabilitation Protocol & Critical Window:
   • Immediate Amplification: Bilateral digital Behind-The-Ear (BTE) hearing aids fitted within weeks of diagnosis, coupled with intensive Auditory-Verbal Therapy (AVT).
   • Cochlear Implantation: Indicated if bilateral severe-to-profound SNHL shows inadequate functional benefit from high-powered hearing aids after a 3- to 6-month trial.
   • Critical Window: Implantation is ideally performed before 12 to 24 months of age to leverage neuroplasticity of the central auditory pathways before functional auditory deprivation leads to cross-modal cortical reorganization.

1. Diagnosis and Anatomical Site:
   • Diagnosis: Spinal Muscular Atrophy (SMA) Type 1 (Werdnig-Hoffmann Disease / Severe Infantile SMA).
   • Anatomical Site: Alpha motor neurons of the anterior horn cells of the spinal cord and motor nuclei of the lower cranial nerves (bulbar motor nuclei: CN IX, X, XII) within the brainstem.
2. Definitive Genetic Assay & Defect:
   • Assay: Multiplex Ligation-dependent Probe Amplification (MLPA) or quantitative Polymerase Chain Reaction (qPCR).
   • Defect: Homozygous deletion (or mutation) of exon 7 (or exons 7 and 8) in the SMN1 (Survival Motor Neuron 1) gene located on chromosome 5q13.2.
3. Phenotypic Variability (Modifier Mechanism):
   • Disease severity is modulated by the copy number of the centromeric paralogous modifier gene, SMN2.
   • SMN2 has a single silent transition mutation ($c.840\text{C}>\text{T}$) in an exonic splicing enhancer in exon 7, causing alternative splicing where 85–90% of transcripts lack exon 7 ($\text{SMN}\Delta7$, an unstable, rapidly degraded truncated protein), while only 10–15% produce functional full-length SMN protein.
   • A lower SMN2 copy number (1 or 2 copies) correlates with the severe SMA Type 1 phenotype, whereas higher copy numbers (3 or 4 copies) produce more functional SMN protein, resulting in milder phenotypes (SMA Types 2, 3, or 4).
4. Disease-Modifying Therapies:
   • Nusinersen (Spinraza):
     • Class: 2'-O-2-methoxyethyl antisense oligonucleotide (ASO).
     • Mechanism: Administered via intrathecal injection; binds to the intronic splice silencer site ($ISS-N1$) in intron 7 of SMN2 pre-mRNA, displacing negative splicing factors and promoting exon 7 inclusion to increase full-length SMN protein production.
   • Onasemnogene Abeparvovec (Zolgensma):
     • Class: Adeno-associated viral vector (AAV9) gene replacement therapy.
     • Mechanism: Administered as a single weight-based intravenous infusion ($1.1 \times 10^{14}\text{ vector genomes/kg}$); crosses the blood-brain barrier and introduces a stable, non-integrating episomal copy of human SMN1 cDNA under a continuous promoter into motor neuron nuclei.
   • Risdiplam (Evrysdi):
     • Class: Orally active small molecule SMN2 splicing modifier.
     • Mechanism: Administered daily via oral/enteral route; selectively modifies pre-mRNA splicing of SMN2 to enhance exon 7 inclusion throughout systemic and central nervous system tissues.

1. Cutaneous Lesion and Diagnosis:
   • Cutaneous Malformation: Port-wine stain (Nevus flammeus).
   • Distribution: Involves the ophthalmic ($V_1$) and maxillary ($V_2$) divisions of the trigeminal nerve (specifically, involvement of the upper eyelid and forehead supplied by $V_1$ carries the highest risk of neuro-ocular involvement).
   • Diagnosis: Sturge-Weber Syndrome (Encephalotrigeminal Angiomatosis).
2. Molecular Pathogenesis:
   • Caused by a postzygotic, somatic mosaic activating mutation in the GNAQ gene (specifically nucleotide substitution $c.548\text{G}>\text{A}$, translating to amino acid substitution $p.\text{Arg}183\text{Gln}$) encoding the $G\alpha_q$ heterotrimeric G-protein subunit.
   • Because the mutation occurs post-zygotically during early embryogenesis in vascular endothelial precursors, it is not present in the germline and is therefore non-heritable (sporadic occurrence).
3. Neuroimaging Features:
   • Non-contrast CT: Cortical and subcortical "tram-track" or gyriform calcifications underlying the region of the vascular malformation (most commonly parieto-occipital).
   • Contrast MRI: Prominent leptomeningeal enhancement (pial angiomatosis) representing venous stasis, ipsilateral hemispheric cerebral cortical atrophy, and prominent, enlarged ipsilateral choroid plexus.
   • Venous Anomalies: Paucity or absence of normal superficial cortical bridging veins with dilated, deep transmedullary collateral veins.
4. Surveillance & Complications:
   • Ipsilateral Glaucoma (Vision-Threatening): Present in 30–70% of cases due to anterior chamber angle anomalies or elevated

1. EEG Findings & Primary Diagnosis:
   • EEG: Radermecker complexes (generalized, periodic, high-amplitude [300–1500 $\mu\text{V}$], stereotypic bilaterally symmetrical, polyphasic slow-wave complexes occurring regularly every 4 to 10 seconds against a slow, suppressed background).
   • Diagnosis: Subacute Sclerosing Panencephalitis (SSPE).
2. Dyken's Diagnostic Criteria:
   • Major Criteria (both must be met or supported by 3 minor criteria):
     • High anti-measles antibody titers in CSF ($\ge 1:4$ or $\ge 1:8$) and/or serum ($\ge 1:256$).
     • Typical or atypical clinical presentation characterized by subacute, progressive intellectual decline and characteristic periodic myoclonus.
   • Minor Criteria:
     • Typical EEG findings (Radermecker periodic complexes).
     • Markedly elevated CSF globulin or oligoclonal bands ($>20\%$ of total CSF protein).
     • Brain biopsy demonstrating panencephalitis with intranuclear/intracytoplasmic viral inclusion bodies.
     • Positive brain tissue molecular analysis (measles virus RNA detected by RT-PCR).
3. Intrathecal Synthesis Derivation:
   $$ > \begin{aligned} > \text{Measles CSF/Serum Antibody Index} &= \frac{[\text{Measles IgG}_{\text{CSF}} / \text{Measles IgG}_{\text{serum}}]}{[\text{Total Albumin}_{\text{CSF}} / \text{Total Albumin}_{\text{serum}}]} \\ > &= > \mathbf{1.5} \quad (\text{Normal} < 1.3) > \end{aligned} > $$
   • A CSF-to-serum anti-measles IgG ratio exceeding $1:4$ to $1:8$ (or antibody index $>1.5$) confirms intrathecal antibody production.
4. Jabbour Staging & Medical Management:
   • Jabbour Staging:
     • Stage I: Insidious behavioral changes, cognitive decline, emotional lability, preserved motor function.
     • Stage II: Massive periodic myoclonic jerks, drop attacks, apraxia, agnosia, chorioretinitis.
     • Stage III: Extrapyramidal symptoms, choreoathetosis, decerebrate/decorticate rigidity, visual loss.
     • Stage IV: Akinetic mutism, stupor/coma, autonomic instability, death.
   • Medical Protocol:
     • Oral Inosiplex (Isoprinosine): $100\text{ mg/kg/day}$ PO divided every 8 hours (maximum $3\text{ g/day}$).
     • Intraventricular/Intrathecal Interferon-alpha: $1\text{ to }3\times 10^6\text{ IU/m}^2$ via subcutaneous Ommaya reservoir once or twice weekly for 6 months.
     • Carbamazepine ($10\text{–}20\text{ mg/kg/day}$) or Sodium Valproate ($20\text{–}30\text{ mg/kg/day}$) for symptomatic myoclonus control.

1. Diagnosis & Triad:
   • Diagnosis: Sydenham Chorea (Chorea Minor / St. Vitus Dance).
   • Classical Triad:
     • Chorea (rapid, involuntary, non-stereotypic purposeless movements).
     • Hypotonia (diminished muscle tone and pendular reflexes).
     • Emotional lability / behavioral disturbances (obsessive-compulsive symptoms, hyperactivity, anxiety).
2. Classic Bedside Examination Signs:
   • Milkmaid’s grip: Inability to maintain sustained tetanic contraction while squeezing the examiner’s fingers due to rhythmic choreic relaxations.
   • Jack-in-the-box tongue (Trombone tongue): Inability to keep the tongue steadily protruded beyond the lips for $\ge 10$ seconds (motor impersistence).
   • Pronator sign: Pronation of the forearm and turning outward of palms when arms are extended above the head.
   • Spooning sign (Choreic hand): Flexion of the wrist with hyperextension of the metacarpophalangeal and interphalangeal joints on forward extension of arms.
3. Essential Investigations:
   • 2D Transthoracic Echocardiography with Doppler: To identify subclinical or clinical carditis (mitral regurgitation/valvulitis).
   • Streptococcal serology & culture: Anti-streptolysin O (ASO) titer, Anti-DNase B titer, and throat swab culture.
   • Systemic inflammatory markers: Erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hs-CRP).
4. Management Protocol:
   • Symptomatic Anti-choreic Pharmacotherapy:
     • Valproic acid: $15\text{–}20\text{ mg/kg/day}$ PO divided into 2 doses (titrated up to $30\text{–}40\text{ mg/kg/day}$), OR
     • Haloperidol: $0.025\text{–}0.05\text{ mg/kg/day}$ PO divided every 8–12 hours (start at $0.5\text{ mg}$ twice daily).
     • Refractory cases: Oral Prednisolone $1\text{–}2\text{ mg/kg/day}$ PO for 4 weeks with tapering.
   • Secondary Antibiotic Prophylaxis (Eradication & Long-Term):
     • Primary Eradication: Single dose Benzathine Penicillin G $1.2\text{ million units}$ IM (or $600,000\text{ units}$ if $<27\text{ kg}$).
     • Secondary Prophylaxis: Intramuscular Benzathine Penicillin G every 3 to 4 weeks until at least 21 years of age or 10 years after the last attack (longer if carditis is present).

1. Diagnosis & Fundus Finding:
   • Diagnosis: Tay-Sachs Disease ($GM_2$ Gangliosidosis, Type 1).
   • Fundus Finding: Bilateral "Cherry-red spot" at the macula (fovea centralis appears vivid red due to transmission of normal underlying vascular choroid, accentuated by the surrounding pale, opacified, lipid-laden retinal ganglion cell layer).
2. Genetics & Enzyme Deficiency:
   • Inheritance: Autosomal recessive.
   • Gene: HEXA gene on chromosome 15q23.
   • Enzyme Deficiency: $\beta$-Hexosaminidase A deficiency (leads to neuronal accumulation of $GM_2$ ganglioside).
3. Pathophysiology of Absent Hepatosplenomegaly:
   • $GM_2$ ganglioside is an acidic glycosphingolipid predominantly expressed and synthesized in neuroectodermal tissues (brain, central nervous system, and retina).
   • Reticuloendothelial cells of the liver and spleen preferentially degrade globosides, glucocerebrosides, and sphingomyelin (accumulating in Gaucher and Niemann-Pick diseases).
   • Because systemic visceral organs lack significant $GM_2$ ganglioside turnover, visceral storage is minimal, resulting in no hepatosplenomegaly.
4. Definitive Diagnosis & Prenatal Screening:
   • Definitive Diagnosis: Quantitative fluorometric or spectrophotometric enzyme assay demonstrating profound deficiency of $\beta$-Hexosaminidase A (with normal or elevated Hexosaminidase B levels) in peripheral blood leukocytes, cultured skin fibroblasts, or plasma.
   • Prenatal Diagnosis:
     • Hexosaminidase A enzyme activity measurement or targeted HEXA mutation analysis via Chorionic Villus Sampling (CVS) at 10–12 weeks of gestation or Amniocentesis at 15–18 weeks of gestation.
     • Pre-implantation genetic testing (PGT-M) on in vitro embryos for couples identified as carrier pairs.

1. Unifying Neurological Diagnosis:
   • Tethered Cord Syndrome (TCS) / Occult Spinal Dysraphism.
2. Underlying Etiologies (Spinal Dysraphic Lesions):
   • Tight / thickened filum terminale (filum thickness $>2\text{ mm}$ or fatty infiltration).
   • Lipomyelomeningocele or spinal lipoma.
   • Split cord malformation (diastematomyelia with bony or fibrous spur).
   • Dermal sinus tract / inclusion epidermoid or dermoid cyst.
3. Cutaneous Lumbosacral Markers:
   • Hypertrichosis (faun-tail nevus or silken hair patch).
   • Capillary hemangioma / Port-wine vascular nevus over the midline spine.
   • Subcutaneous lipoma or acrochordon (skin tag/pseudotail).
   • Atypical sacral dimple (diameter $>5\text{ mm}$, located $>2.5\text{ cm}$ above the anal verge, or within the superior intergluteal fold).
4. Neuroimaging & Management:
   • Imaging Modality: Magnetic Resonance Imaging (MRI) of the whole spine (T1- and T2-weighted sagittal and axial sequences).
   • Diagnostic Imaging Finding: Abnormally low-lying conus medullaris terminating below the inferior endplate of the L2 vertebral body (normal position in children $>3$ months of age is at or above L1–L2 interspace), associated with a thickened filum terminale ($>2\text{ mm}$) and dorsal displacement of the cord.
   • Definitive Treatment: Microsurgical detethering of the spinal cord (e.g., sectioning of the filum terminale, excision of the dysraphic bony spur or lipoma) to prevent irreversible ischemic neuronal injury.

1. Spinal Cord Level:
   • T10 spinal cord level (loss of all sensory modalities below the umbilicus, which corresponds precisely to the T10 dermatome).
2. Beevor Sign & Mechanism:
   • Sign: Positive Beevor sign (upward/cranial migration of the umbilicus during neck flexion or sitting attempt).
   • Pathophysiology: Selective preservation of upper abdominal wall musculature (rectus abdominis innervated by T6–T9) with paralysis of the lower abdominal musculature (innervated by T10–T12). Contraction of the intact upper fibers pulls the umbilicus upward toward the head.
3. Hemodynamic State:
   • Condition: Neurogenic shock.
   • Physiology: Disruption of descending sympathetic autonomic pathways within the thoracic spinal cord ($T1\text{–}L2$), leading to unchecked parasympathetic (vagal) tone resulting in bradycardia (HR 54/min) and loss of vascular vasomotor tone causing diffuse arterial/venous vasodilation and hypotension (BP 80/46 mm Hg).
4. Target MAP & Pediatric Phenomenon:
   • MAP Target Calculation:
     $$ > \begin{aligned} > \text{Current MAP} &= \text{DBP} + \frac{1}{3}(\text{SBP} - \text{DBP}) \\ > &= 46 + \frac{1}{3}(80 - 46) = \mathbf{57.3\text{ mm Hg}} \\ > \text{Target MAP} &= \mathbf{85\text{ to }90\text{ mm Hg}} \quad (\text{Maintained for 5 to 7 days}) > \end{aligned} > $$
     • Manage with isotonic crystalloid boluses followed by vasoactive support (Norepinephrine or Epinephrine infusion).
   • Unique Phenomenon: SCIWORA (Spinal Cord Injury Without Radiologic Abnormality), attributable to the heightened elasticity and flexibility of the pediatric vertebral column relative to the fragile, less elastic spinal cord.

1. Neuroimaging Findings and Diagnosis:
   • MRI findings: Destruction of adjacent vertebral bodies (T12–L1) with narrowing/collapse of the intervening intervertebral disc space, anterior subligamentous spread, pre- and paravertebral cold abscess collection, and posterior epidural extension with cord compression.
   • Diagnosis: Tubercular spondylodiscitis (Spinal tuberculosis / Pott spine).
2. Anatomical Predilection and Predisposing Factors:
   • Most common site: Thoracolumbar junction (T10–L2), followed by the lower thoracic spine.
   • Predisposing factors:
     • Area of maximum mechanical motion and weight-bearing stress.
     • Valveless intraosseous and perivertebral venous plexus of Batson, allowing retrograde haematogenous embolization from pelvic or abdominal organs during intra-abdominal pressure changes.
3. Bedside Clinical Signs:
   • Coin test (Pick-up test): When asked to pick up a coin from the floor, the child avoids bending the spine; instead, flexes at the knees and hips while maintaining the back held strictly rigid.
   • Coin sign / Knuckle kyphosis (Gibbus deformity): Palpation of a prominent, angular posterior spinal step-off or knuckle due to collapse of anterior vertebral body cortex.
4. Pharmacotherapy Regimen (NTEP / WHO Guidelines):
   • Intensive Phase (2 months): 4 drugs daily — HRZE
     • Isoniazid (H): $10\text{ mg/kg/day}$ (max $300\text{ mg/day}$)
     • Rifampicin (R): $15\text{ mg/kg/day}$ (max $600\text{ mg/day}$)
     • Pyrazinamide (Z): $30–35\text{ mg/kg/day}$ (max $2000\text{ mg/day}$)
     • Ethambutol (E): $20\text{ mg/kg/day}$ (max $1000\text{ mg/day}$)
   • Continuation Phase (10 months): 3 drugs daily — HRE (Total duration: 12 months for bone/joint tuberculosis).
   • Pyridoxine supplementation ($10–25\text{ mg/day}$) to prevent peripheral neuropathy.

• Rapidly progressive or unresolving neurological deficit (paraparesis/paraplegia).
• Marked spinal instability or progressive kyphotic deformity ($>40^\circ$).
• Large unresolving prevertebral or psoas abscess causing mechanical or respiratory compromise.
• Diagnostic uncertainty failure to respond after 4–6 weeks of empiric antitubercular therapy.

1. Calculations and Diagnostic Interpretation:
   $$ > \begin{aligned} > \text{CSF:Blood Glucose Ratio} &= \frac{\text{CSF Glucose}}{\text{Simultaneous Blood Glucose}} \\ > &= \frac{18\text{ mg/dL}}{108\text{ mg/dL}} \\ > &= \mathbf{0.167} \quad (\text{Normal } \ge 0.60; \text{Markedly reduced } < 0.30) > \end{aligned} > $$
   • Cobweb / Pellicle formation: High fibrinogen content along with high total protein ($>400\text{ mg/dL}$) precipitating when allowed to stand undisturbed.
   • Likely Diagnosis: Tubercular Meningitis (TBM - Stage II).
   • Infectious Mimics: Cryptococcal (fungal) meningitis, partially treated acute bacterial meningitis, neurolisteriosis.
2. Cranial Nerve Involvement and Mechanism:
   • Cranial Nerve: Right Sixth cranial nerve (Abducens nerve).
   • Mechanisms:
     • Entrapment by dense, gelatinous basal exudates in the interpeduncular and prepontine cisterns.
     • False-localizing sign secondary to stretching over the petrous temporal ridge in the setting of raised intracranial pressure (longest intracranial course).
3. Anti-inflammatory and Anti-edema Therapy:
   • Systemic Corticosteroids: Dexamethasone $0.4\text{ mg/kg/day}$ IV divided q6–8h (or Prednisolone $2–4\text{ mg/kg/day}$ oral) for 4 weeks, followed by a gradual taper over 2–4 weeks.
   • Rationale: Reduces cerebral edema, suppresses basal meningeal inflammatory exudates, lowers incidence of hydrocephalus and vasculitic cerebral infarction.
   • Acute hyperosmolar therapy for herniation risk: $20\%$ Mannitol $0.5–1.0\text{ g/kg}$ ($2.5–5\text{ mL/kg}$) IV over 20 minutes or $3\%$ Hypertonic Saline $3–5\text{ mL/kg}$ IV over 15 minutes.
4. Definitive Antitubercular Therapy (ATT):
   • Intensive Phase (2 months): 4 daily drugs
     • Isoniazid (H): $10\text{ mg/kg/day}$ (max $300\text{ mg/day}$)
     • Rifampicin (R): $15\text{ mg/kg/day}$ (max $600\text{ mg/day}$)
     • Pyrazinamide (Z): $30–35\text{ mg/kg/day}$ (max $2000\text{ mg/day}$)
     • Ethambutol (E): $20\text{ mg/kg/day}$ (max $1000\text{ mg/day}$)
   • Continuation Phase (10 months): 2 or 3 drugs (HRE) daily for a total ATT duration of 12 months.

1. Lesion and Diagnosis:
   • Dermatological lesion: Facial angiofibromas (historically termed Adenoma sebaceum).
   • Diagnosis: Tuberous Sclerosis Complex (TSC / Bourneville disease).
2. Major Diagnostic Criteria (Any 4 of the following):
   • Hypomelanotic macules ($\ge 3$, at least $5\text{ mm}$ diameter)
   • Angiofibromas ($\ge 3$) or fibrous cephalic plaque
   • Ungual / periungual fibromas (Koenen tumors) ($\ge 2$)
   • Shagreen patch (connective tissue nevus)
   • Multiple retinal hamartomas
   • Multiple cortical tubers and/or radial migration lines
   • Subependymal nodules (SENs) ($\ge 2$)
   • Subependymal giant cell astrocytoma (SEGA)
   • Cardiac rhabdomyoma
   • Lymphangioleiomyomatosis (LAM)
   • Renal angiomyolipoma ($\ge 2$)
3. Intracranial Lesions and Targeted Therapy:
   • Neuroimaging lesions: Cortical / subcortical tubers, subependymal nodules (SENs), and subependymal giant cell astrocytomas (SEGAs, usually near the Foramen of Monro).
   • Targeted pharmacotherapy: mTOR inhibitors — Everolimus ($4.5\text{ mg/m}^2/\text{day}$ titrated to target trough levels of $5–15\text{ ng/mL}$) or Sirolimus.
4. Infantile Spasms Pharmacotherapy and Monitoring:
   • Drug of choice: Vigabatrin (oral $100–150\text{ mg/kg/day}$ divided bid).
   • Mandatory safety monitoring: Baseline and 3-monthly visual field testing / electroretinogram (ERG) due to the risk of irreversible, concentric, bilateral peripheral visual field constriction.

1. EEG Pattern and Triad:
   • EEG pattern: Hypsarrhythmia (characterized by high-voltage, chaotic, disorganized background slowing with multifocal, asynchronous spike-and-wave discharges).
   • Classic Triad of West Syndrome:
     • Epileptic spasms (infantile spasms in clusters)
     • Psychomotor / developmental arrest or regression
     • Interictal hypsarrhythmia on EEG
2. ILAE Etiological Classification:
   • Structural: Hypoxic-ischemic encephalopathy (periventricular leukomalacia / perinatal stroke), focal cortical dysplasia.
   • Genetic: Trisomy 21 (Down syndrome), CDKL5, ARX, STXBP1 gene mutations, Tuberous Sclerosis Complex (TSC1/TSC2).
   • Metabolic: Pyridoxine-dependent epilepsy, nonketotic hyperglycinemia, phenylketonuria.
   • Unknown (Cryptogenic): Normal development prior to onset with no structural or identifiable etiology.
3. First-line Hormonal Treatment Protocol:
   • Adrenocorticotropic Hormone (ACTH):
     • High-dose natural/synthetic ACTH: $150\text{ IU/m}^2/\text{day}$ (or synthetic depot tetracosactide $0.5–1\text{ mg/day}$) intramuscularly for 2 weeks.
     • Followed by a gradual tapering schedule over an additional 2 to 4 weeks.
     • Alternative oral hormonal regimen: Oral Prednisolone $40–60\text{ mg/day}$ ($4\text{ mg/kg/day}$ in divided doses) for 2 weeks followed by a 2-week taper.
4. Management for Tuberous Sclerosis-Associated Spasms:
   • Drug of choice: Vigabatrin (oral).
   • Mechanism of Action: Irreversible selective suicide inhibitor of GABA transaminase (GABA-T), producing sustained elevation of synaptic $\gamma$-aminobutyric acid (GABA) concentrations.
   • Target Dosing: Initiated at $50\text{ mg/kg/day}$ orally in 2 divided doses; rapidly titrated every 3 days up to $100–150\text{ mg/kg/day}$.